

## Current Concepts and Challenges in Osteochondral Tissue Engineering and Regenerative Medicine

Leping Yan, Joaquim Miguel Oliveira, Ana Leite Oliveira, and Rui L. Reis

ACS Biomater. Sci. Eng., **Just Accepted Manuscript** • DOI: 10.1021/ab500038y • Publication Date (Web): 20 Feb 2015

Downloaded from <http://pubs.acs.org> on February 25, 2015

### Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

# Current Concepts and Challenges in Osteochondral Tissue Engineering and Regenerative Medicine

*Le-Ping Yan,<sup>†‡</sup> Joaquim M. Oliveira,<sup>\*†‡</sup> Ana L. Oliveira,<sup>†‡§</sup> Rui L. Reis<sup>†‡</sup>*

<sup>†</sup>3B's Research Group–Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, AvePark, S. Cláudio de Barco, 4806-909 Taipas, Guimarães, Portugal.

<sup>‡</sup>ICVS/3B's–PT Government Associate Laboratory, Braga/Guimarães, Portugal.

<sup>§</sup>CBQF–Center for Biotechnology and Fine Chemistry, School of Biotechnology, Portuguese Catholic University, Porto, 4200 – 072, Portugal.

\*Corresponding Author: Dr. Joaquim M. Oliveira (E-mail: miguel.oliveira@dep.uminho.pt)

## Abstract

In the last few years, great progress has been made to validate tissue engineering strategies in preclinical studies and clinical trials on the regeneration of osteochondral defects. In the preclinical studies, one of the dominant strategies comprises the development of biomimetic/bioactive scaffolds, which are used alone or incorporated with growth factors and/or stem cells. Many new trends are emerging for modulation of stem cell fate towards osteogenic and chondrogenic differentiations, but bone/cartilage interface regeneration and physical stimulus have been showing great promise. Besides the matrix-associated autologous chondrocyte implantation (MACI) procedure, the matrix-associated stem cells implantation (MASI) and layered scaffolds in acellular or cellular strategy are also applied in clinic. This review outlines the progresses at preclinical and clinical levels, and identifies the new challenges in osteochondral tissue engineering. Future perspectives are provided, e.g., the applications of extracellular matrix-like biomaterials, computer-aided design/manufacture of osteochondral implant and reprogrammed cells for osteochondral regeneration.

**Keywords:** Osteochondral tissue engineering; Layered scaffold; Biomimetic; Interface engineering; Clinical trial, Pluripotent stem cells

## Introduction

Articular cartilage is a connective tissue that acts as a shock absorber and facilitates joint's motion in low friction.<sup>1</sup> Many reasons can lead to cartilage lesions, such as traumatic events, chronic repetitive microtrauma, and aging. Cartilage lesions are normally irreparable due to the typical avascular nature of cartilage and consequent lack of supplementation of potentially reparative cells/bioactive factors.<sup>2</sup> As the cartilage lesion progresses, it extends to the underlying subchondral bone and osteochondral defect (OCD) appears. Other diseases originating from the subchondral bone and subsequently reaching the cartilage layer can also induce OCD, such as osteochondritis dissecans and osteonecrosis.<sup>3</sup> Osteochondral (OC) fracture, which is a common injury in children and adolescents, represents one cause for OCD. Besides the OCD in the knee, nowadays an increasing amount of attention is being given to OC lesions of the talus (OLTs) because they primarily affect young athletic population and often lead to long-term disability.<sup>4, 5</sup> Similarly, OC fractures of the patella represent a major complication following patellar instability or dislocation.<sup>6</sup> OCD often causes the formation of fibrocartilage which only provides poor protection to the subchondral bone. Subsequent degradation of the repaired and adjacent tissues is often observed.<sup>2</sup> Furthermore, OCD is associated with severe pain, impaired joint mobility and low quality of life. It also generates huge amount of health care costs every year. In the United States alone, the annual cost for the treatment of OCD is about \$95 billion.<sup>7</sup>

There has been increased evidence that without the support from the subchondral bone, any treatment of the cartilage layer is likely to fail.<sup>3, 8</sup> Thus, the cartilage and subchondral bone should be taken into account as one unit during OC regeneration, instead of being considered separately. Actually, the cartilage layer and subchondral bone are tightly connected. No matter what type of the lesion it is, either from the cartilage or from the subchondral bone, the

1  
2  
3 connected and surrounding tissues will always be affected, contributing negatively to the  
4 mechanical homeostasis of the whole joint. Therefore, the main goal for OC regeneration is to  
5 restore its biomechanical properties, besides the regeneration of the defect.  
6  
7

8  
9  
10 Currently, there are several methods used in the clinical setting for treating OCD.  
11 Arthroscopic debridement is used to trim the loose cartilage in small defects and only for the  
12 relief of pain for the patients. For defects between 1 and 2.5 cm<sup>2</sup>, microfracture is commonly  
13 selected.<sup>9</sup> For this method, microfractures are created from the cartilage defect until reaching the  
14 subchondral bone. The access of mesenchymal stem/stromal cells (MSCs) and growth factors  
15 from bone marrow and blood facilitates the formation of fibrocartilage on the defect. Patients  
16 who received this treatment often need revision interventions after some time, i.e. some  
17 degradation of the tissue was reported around 18 months post-operatively. Arthroscopic  
18 debridement and microfracture are palliative methods for OCD treatment. OC autograft  
19 transplantation (mosaicplasty, OATS) constitutes another option if the defect size is between 1  
20 and 4.0 cm<sup>2</sup>.<sup>10, 11</sup> However, this method would create new OCD in the body and has limited  
21 availability of the donor tissues. For lesions of size higher than 2.5 cm<sup>2</sup>, autologous chondrocyte  
22 implantation (ACI) technology has been widely used. This method presents an advantage of  
23 possibly achieving regeneration with hyaline cartilage. However it requires two-step surgeries  
24 and may induce complications of chondrocyte apoptosis and necrosis, or hypertrophy of the  
25 cells.<sup>12, 13</sup>  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

48 Recently, tissue engineering strategy emerged as a promising alternative to regenerate OCD.<sup>14</sup>  
49 Tissue engineering is a multi-disciplinary approach, involving the advances in material science,  
50 chemical engineering, biology, and medicine.<sup>15</sup> Probably the currently most appealing clinical  
51 application of tissue engineering for OC regeneration is the matrix-associated autologous  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 chondrocyte implantation (MACI) technology.<sup>16</sup> In order to achieve ideal OC regeneration,  
4 numerous efforts have been made on scaffold/hydrogel development, stem cells differentiation,  
5 growth factors incorporation, and animal models.<sup>14, 17-19</sup> Furthermore, a few studies have been  
6 extended to clinical trials.<sup>20-22</sup> Many important and interesting findings were made, and some  
7 new technologies and subjects have emerged during the last few years.<sup>23-25</sup>

8  
9  
10 In this review, the most important breakthroughs in OC tissue engineering in the past few  
11 years were overviewed. Moreover, this review also intends to add new insights regarding the  
12 current research status and challenges in OCD preclinical studies and clinical trials using tissue  
13 engineering strategies. In addition, the new trends and future directions in OC tissue engineering  
14 are briefly discussed.

## 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 **Tissue Engineering Strategies in OC Regeneration**

### 30 31 32 **In Vitro Studies on OC Tissue Engineering**

33 Biomaterials, bioactive agents, and cells are the three key factors for tissue engineering strategy.  
34 A lot of biomaterials have been explored for OC regeneration in vitro. These materials include  
35 synthetic or natural polymers, bioceramics, and composites of these materials.<sup>26-29</sup> It is necessary  
36 to study the biological performances of these materials by in vitro cell culture after processing  
37 them into different formats, such as porous scaffolds and hydrogels of non-layered or layered  
38 structure.<sup>30-32</sup>

#### 39 40 41 42 43 44 45 46 47 48 49 50 ***Layered scaffolds***

51 As a stratified tissue, OC tissue is composed of collagen (Col) II and glycosaminoglycan (GAG)  
52 in the hydrogel-like cartilage layer, and hydroxyapatite (HA) and Col I in the highly porous  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 subchondral bone layer.<sup>26</sup> Inspired by the structure and components of OC tissue, biomimetic  
4 strategies have been introduced to produce scaffolds displaying similar structural or chemical  
5 properties to OC tissue.<sup>26</sup> For example, layered constructs which presented similar  
6 microenvironments to the corresponding layers of OC tissue were studied intensively.<sup>26, 33, 34</sup>  
7  
8  
9  
10  
11

12 Oliveira et al. developed a well-integrated bilayered porous HA and chitosan scaffold.<sup>26</sup>  
13 Osteogenic differentiation (14 days) and chondrogenic differentiation (28 days) of goat bone  
14 marrow mesenchymal stromal cells (BMSCs) were performed on the separated HA and chitosan  
15 layers, respectively. Results showed that the alkaline phosphatase (ALP) content increased in the  
16 HA scaffolds after 2 weeks osteogenic differentiation. Osteopontin and Col I were also observed  
17 in the HA scaffolds via the immunofluorescence labeling. The chitosan scaffolds presented  
18 enhanced GAG content from day 7 to 21. In another study, multilayered porous scaffolds were  
19 developed which consisted of gradient HA content between the collagen and the collagen/HA  
20 layers.<sup>34</sup> Human BMSCs (hBMSCs) were seeded onto the separated collagen and collagen/HA  
21 layers, and then both the chondrogenic differentiation (28 days) and osteogenic differentiation  
22 (14 days) of the cells were performed for these two groups of scaffolds, respectively. The  
23 chondrogenic differentiation results showed that the collagen layer induced superior  
24 chondrogenic genes (Sox-9, Col 2a1 and aggrecan) expressions compared with the collagen/HA  
25 layer at day 21. Furthermore, the GAG contents in the collagen layer were higher than the ones  
26 in the collagen/HA layer at day 14 and 28. In case of osteogenic differentiation, the collagen/HA  
27 layer showed superior ALP content at day 5, 10 and 13, and displayed higher amounts of Runx-  
28 2, ALP, Col 1a1, osteopontin and osteocalcin genes at day 14, compared with the ones of the  
29 collagen layer.  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Mimicking the micromechanical environment of OC tissue, hydrogels and porous scaffolds  
4 were combined to form bilayered scaffolds.<sup>31, 32, 35</sup> In one study from Hung et al., agarose with  
5 encapsulated bovine chondrocytes was penetrated into the devitalized bovine tibia trabecular  
6 bone to generate the cylindrical bilayered OC construct.<sup>35</sup> The constructs were cultured in  
7 Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum  
8 (FBS) and 50 µg/ml ascorbic acid for 42 days. They also produced chondrocytes-seeded agarose  
9 of anatomical patellar shape and then integrated the agarose constructs with trabecular bone of  
10 corresponding anatomical shape to form the osteochondral constructs which were subsequently  
11 cultured in the above mentioned medium for two weeks. Results showed that the chondrocytes  
12 were viable in these two experiments and the agarose still firmly integrated with the bony  
13 substrate during the culture time periods. These constructs presented positive Col II staining, as  
14 well as enhanced GAG contents and mechanical properties. In a following study, hBMSCs were  
15 pre-differentiated into chondrocytes and osteoblasts for 1 week firstly and then these cells were  
16 incorporated into the agarose (chondrocytes) layer and decellularized trabecular bone layer  
17 (osteoblasts) of the bilayered scaffolds, respectively.<sup>32</sup> Undifferentiated hBMSCs were used as  
18 control and seeded into the same bilayered scaffolds. The constructs were placed into perfusion  
19 bioreactors and cultured in either chondrogenic medium or cocktail medium containing  
20 chondrogenic and osteogenic supplements for 5 weeks. The control constructs were kept under  
21 static or bioreactor culture in the chondrogenic or cocktail medium for 5 weeks. It was found  
22 that pre-differentiated BMSCs only favored bone formation, while the perfusion condition and  
23 cocktail medium inhibited chondrogenesis of BMSCs. The perfusion bioreactor was helpful to  
24 improve the integration of bone-cartilage interface. In order to further efficiently guide the cells  
25 toward OC differentiate, new culture technologies should be explored.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



### *Biological cues*

It has been reported that some growth factors or drugs are efficient in modulation of cellular differentiation. For example, transforming growth factor- $\beta$ 1 (TGF- $\beta$ 1) or transforming growth factor- $\beta$ 3 (TGF- $\beta$ 3) can induce chondrogenesis of the MSCs, and bone morphogenetic proteins (BMP) are suitable for guiding the osteogenesis of MSCs.<sup>36, 37</sup> These bioactive reagents have been introduced into the scaffolds to improve the cellular differentiation toward OC regeneration.

Guo et al. developed bilayered poly(ethylene glycol) fumarate hydrogels (OPF) which contained gelatin microparticles loaded with TGF- $\beta$ 1 in the chondral layer.<sup>28</sup> The chondral layer encapsulated undifferentiated rabbit BMSCs, while the bony layer consisted of rabbit BMSCs or osteogenically differentiated BMSCs (6 days). Bilayered hydrogels only with BMSCs and unloaded microparticles, or bilayered hydrogels with BMSCs in the chondral layer and osteogenically differentiated BMSCs in the bony layer and blank microparticles, were used as controls. All the constructs were cultured in chondrogenic medium supplemented with  $\beta$ -glycerol phosphate ( $\beta$ -GP) for 28 days. The results showed that chondrogenesis was observed in the chondral layer, especially in the presence of TGF- $\beta$ 1. In the bony layer, osteoblastic phenotype of the cells was maintained. Calcium deposition was limited, but this layer promoted chondrogenic differentiation of BMSCs in the chondral layer. The optimal results were displayed in the group with growth factor loaded microparticles and osteogenic differentiated BMSCs. In another similar study, gelatin microparticles loaded with rabbit BMSCs and TGF-  $\beta$ 3 were incorporated into the chondral layer of the bilayered OPF hydrogels.<sup>36</sup> BMSCs undergone varied osteogenic differentiation time periods (0, 3, 6, 12 days) were encapsulated into the bony layer of the bilayered OPF hydrogels. Bilayered hydrogels including chondral layer without growth

1  
2  
3 factor but bony layer with BMSCs of varied osteogenic differentiation time were used as  
4 controls. All the bilayered constructs were cultured in chondrogenic medium plus  $\beta$ -GP for 28  
5 days. In the chondral layer, TGF- $\beta$ 3 significantly promoted chondrogenic differentiation of  
6 BMSCs. Osteogenically differentiated cells along with TGF- $\beta$ 3 improved the chondrogenic gene  
7 expression of the BMSCs. In the bony part, cells maintained ALP activity during coculture,  
8 while mineralization was delayed in the presence of TGF- $\beta$ 3.  
9

10  
11  
12  
13  
14  
15  
16  
17  
18 Spatiotemporal modulation of the delivery of growth factors in the scaffolds is essential for  
19 guiding the BMSCs differentiation during OC regeneration. Bone morphogenetic protein-2  
20 (BMP-2) and TGF- $\beta$ 1 loaded poly(lactic-co-glycolic acid) (PLGA) microspheres were used to  
21 fabricate microsphere based PLGA scaffolds with opposite gradient of the two growth factors by  
22 Dormer et al.<sup>37</sup> Human BMSCs (hBMSCs) or human umbilical cord mesenchymal stromal cells  
23 (UCMSCs) were seeded onto these scaffolds. The constructs were cultured in defined DMEM  
24 for the first three days and then in defined medium supplemented with  $\beta$ -GP and dexamethasone  
25 for 6 weeks. Blank scaffolds, single phase scaffolds (with BMP-2 or TGF-  $\beta$ 1), or biphasic  
26 scaffolds (with BMP-2 or TGF-  $\beta$ 1 in each layer) were used as controls. The results  
27 demonstrated that the hBMSCs responded well to the gradient design through their gene  
28 expressions (Col I, Sox9 and Runx2), but there were no significant differences compared with  
29 UCMSCs in terms of the biochemical performances (DNA, GAG, ALP and hydroxyproline  
30 contents). The gradient scaffolds produced regionalized extracellular matrix (ECM), and were  
31 superior as compared with the blank control scaffolds in cellular number, GAG production,  
32 collagen content, and ALP activity. In another study, Wang et al. incorporated recombinant  
33 human BMP (rhBMP) and recombinant human insulin-like growth factor-1 (rhIGF-1) in PLGA  
34 or silk microparticles.<sup>38</sup> Next, these growth factors were distributed in cylindrical alginate gels or  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 aqueous derived salt-leached silk scaffolds with a gradient concentration of one growth factor or  
4 reverse gradient concentrations of these two growth factors. The influences of the gradient  
5 concentration of the growth factors on hBMSCs were investigated by seeding the cells onto the  
6 scaffolds or encapsulating the cells in the gels. The constructs were cultured in medium  
7 containing osteogenic and chondrogenic components for 5 weeks. In the case of alginate gels, it  
8 was found that silk microspheres were more efficient in rhBMP-2 delivery and less efficient in  
9 delivering rhIGF-1 compared with PLGA microspheres. The growth factor gradients induced  
10 non-gradient trends in hMSCs OC differentiation, due to shallow gradients. Regarding the silk  
11 scaffold group, the cells presented osteogenic and chondrogenic differentiations along the  
12 gradient concentration of rhBMP-2 or reverse gradient of rhBMP-2/rhIGF-1, but not in the  
13 rhIGF-1 gradient system.

14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

The above mentioned studies provide useful insights for OC regeneration, as well as for creation of complex tissues. In the future, development of growth factors of low cost, such as from human platelet releasate, would be of great interest.<sup>39</sup>

### ***Stem cells***

Besides primary cells (osteoblasts and chondrocytes), increasing attention has been shifted to stem cells for OC regeneration, such as BMSCs, adipose tissue-derived stem cells (ADSCs), UCMSCs and amniotic fluid-derived stem cells (AFSCs).<sup>26, 40-42</sup>

In the studies from Guo et al., the osteogenically pre-differentiated BMSCs were encapsulated in the OPF hydrogels and the cells maintained their osteoblastic phenotype and ALP activity, even though the calcium deposition was limited or delayed.<sup>28, 36</sup> Dormer et al. compared the human BMSCs and UCMSCs by seeding them in growth factor loaded PLGA scaffolds and

1  
2  
3 found that there were no significant differences between these cells regarding biochemical  
4 performances.<sup>37</sup> ADSCs were seeded onto the electrospun poly( $\epsilon$ -caprolactone) (PCL) scaffolds  
5  
6 with opposite gradient concentrations of insulin and  $\beta$ -GP, and the constructs were cultured for 8  
7  
8 weeks.<sup>40</sup> The results showed that chondrogenic differentiation of the cells increased in the  
9  
10 insulin-rich region and mineralization matrix enhanced at  $\beta$ -GP rich domain. In another study,  
11  
12 AFSCs were encapsulated into agarose gels (chondral layer) or seeded onto the starch-PCL  
13  
14 (SPCL) scaffolds (bony layer) and subsequently the constructs underwent chondrogenic or  
15  
16 osteogenic differentiations, respectively.<sup>42</sup> After chondrogenic and osteogenic differentiations  
17  
18 occurring, the agarose and SPCL constructs were integrated by agarose solution and the formed  
19  
20 bilayered constructs were cultured under OC co-culture medium or OC co-culture medium plus  
21  
22 insulin-like growth factor-1 (IGF-1) for 2 weeks. Basic amniotic fluid cell medium was used as  
23  
24 control. Results displayed that osteogenically pre-differentiated AFSCs did not need further OC  
25  
26 medium to maintain their phenotype, while the chondrogenically pre-differentiated ones still  
27  
28 required OC medium (without IGF-1) to maintain their phenotypes.  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38


### 39 ***Interface regeneration***

40  
41 During OC regeneration, most of the attention has been given to the generation of the integrated  
42  
43 cartilage layer and the subchondral layer. Only recently, there is increased awareness that the  
44  
45 regeneration of the interface between chondral and subchondral bone also plays an important  
46  
47 role in OC tissue engineering.<sup>23</sup> The OC interface is a calcified cartilage layer located between  
48  
49 the hyaline cartilage and the subchondral bone.<sup>23, 35, 43</sup> The hypertrophic chondrocytes and  
50  
51 extracellular matrix rich in Col I, II, and X, are the unique properties of this layer. The OC  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 interface acts as a barrier minimizing the diffusions of fluids between cartilage layer and  
4  
5 subchondral layer, and therefore prevents the invasion of vessels from bone.  
6  
7

8 Bioactive inorganic biomaterials have been used to direct the differentiation of chondrocytes  
9  
10 toward the formation of calcified cartilage. In the study from Jiang et al., agarose gel with  
11  
12 encapsulated bovine chondrocytes was firstly integrated with PLGA/bioactive glass microsphere  
13  
14 scaffold and then bovine osteoblasts were subsequently seeded onto the PLGA/bioactive glass  
15  
16 part.<sup>44</sup> These multi-phased OC constructs contained a hybrid gel/microsphere interface region  
17  
18 between the gel (chondral) and scaffold (bony) layers. The constructs were cultured in DMEM  
19  
20 plus ascorbic acid for 20 days. Constructs without bioactive glass were used as control. It was  
21  
22 found that the co-culture of chondrocytes and osteoblasts resulted in three distinct yet continuous  
23  
24 regions: cartilage, calcified cartilage and bone-like matrices. The PLGA/bioactive glass phase  
25  
26 facilitated the formation of calcified interface and promoted chondrocyte mineralization potential  
27  
28 around the interface region. Khanarian et al. incorporated bovine deep zone chondrocytes into  
29  
30 alginate gels with 1.5 wt/v% HA particles (20  $\mu\text{m}$ ).<sup>45</sup> The constructs were cultured for 4 weeks in  
31  
32 DMEM supplemented with ITS Premix, proline and ascorbic acid. Constructs without HA were  
33  
34 used as control. The results showed that the HA phase enhanced the formation of GAG and Col  
35  
36 II, and also increased mechanical properties as compared with the control. Presence of HA  
37  
38 promoted hypertrophy of the chondrocyte, as well as Col X deposition in the constructs. In  
39  
40 another study from the same group, the authors encapsulated bovine deep zone chondrocytes and  
41  
42 triiodothyronine (T3)-induced hypertrophic deep zone chondrocytes in agarose/HA hybrid gels  
43  
44 to mimic the calcified cartilage formation. They studied the different influences of nano-sized  
45  
46 and micro-sized HA particles on the hypertrophy of chondrocytes.<sup>43</sup> The constructs were  
47  
48 cultured for 14 days in DMEM supplemented with ITS Premix, proline and ascorbic acid.  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Acellular hybrid gels were used as control (**Figure 1**). It was found that the hypertrophic chondrocytes presented higher ECM and mineral deposition in the presence of HA compared



**Figure 1.** The influence of HA on hypertrophic chondrocytes after culturing in agarose/HA gels for 14 days. (A) Effect of HA presence (1.5 w/v% HA) and size (micro and nano-sized) on the biosynthesis and mineralization. Alcian Blue stain (GAG) revealed abundant matrix for the micro-HA group. The immunohistochemistry analysis showed positive Col II and minimal Col I stainings for all the groups, while positive Col X staining was found in the HA containing groups no matter the particle size. Strongly positive mineral staining was seen in the micro-HA group (Alizarin Red and Von Kossa). (B) Effect of HA presence and size on the gene expressions. Both Col X and Ihh expression were upregulated. (C) Effect of HA dose (micro-sized) on the gene

1  
2  
3 expressions. A dose-dependent increase in Col X expression was found. Suppression of PTHrP  
4  
5 and Ihh expressions were found at the higher HA doses (3% and 6% HA,  $*p < 0.05$ ,  $n=3$   
6  
7 normalized to 0% group). Adapted from Reference (43), with permission from Elsevier.  
8  
9

10  
11  
12 with non-induced chondrocytes. Higher compressive and shear mechanical properties were  
13  
14 observed in the constructs as compared with the acellular ones. Cell hypertrophy was  
15  
16 independent of ceramic size, while higher ECM deposition was only displayed in the micro-sized  
17  
18 HA group. Allan et al. firstly seeded cow deep zone chondrocytes on top of the calcium  
19  
20 polyphosphate (CPP) scaffolds and then cultured the constructs in DMEM supplemented with  
21  
22 ascorbic acid.<sup>46</sup> At day 7,  $\beta$ -GP was added in the medium and the culture was continued up to 8  
23  
24 weeks. Control culture was without  $\beta$ -GP. The results showed that cartilage tissue formed and  
25  
26 presented two zones, one calcified region adjacent to the CPP scaffold and a hyaline-like zone on  
27  
28 the surface. Little or no mineral was observed in the absence of  $\beta$ -GP. The mineral in the  
29  
30 calcified region was HA. The formed cartilage tissue possessed significantly higher stiffness and  
31  
32 interfacial shear properties compared with the control.  
33  
34  
35  
36  
37

38  
39 Besides the primary cells, stem cells have also been investigated for OC interface  
40  
41 regeneration.<sup>47</sup> Cheng et al. encapsulated rabbit BMSCs into collagen microspheres and then  
42  
43 cultured the microspheres under chondrogenic or osteogenic conditions for 21 days.<sup>23</sup> Following,  
44  
45 microspheres of each group were packed and glued for continued co-culture for another 21 days.  
46  
47 The resulted disc-like chondrogenic and osteogenic aggregates were glued together by a middle  
48  
49 layer of collagen gel containing undifferentiated BMSCs. The tri-layered collagen microsphere  
50  
51 scaffolds were co-cultured under normal, chondrogenic or osteogenic medium for 14 or 21 days.  
52  
53 When co-culture was performed in the chondrogenic medium, the results showed that an intact  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 and continuous calcified cartilage zone was formed separating the upper chondrogenic layer and  
4 the underlying osteogenic layer. Cells at the interface region presented hypertrophic phenotype.  
5  
6 Col II and X, calcium mineral and vertically oriented fibers were presented in the ECM. In the  
7  
8 case of osteogenic medium, the upper layer chondrogenic tissue became calcified. In the normal  
9  
10 medium, undifferentiated BMSCs were found in the interface, and the pre-differentiated BMSCs  
11  
12 were able to maintain their chondrogenic or osteogenic phenotypes. UCMSCs were applied for  
13  
14 OC regeneration via a sandwich strategy by Wang et al.<sup>41</sup> The human UCMSCs were firstly  
15  
16 cultured in the PLLA scaffolds and underwent chondrogenic or osteogenic differentiation for 3  
17  
18 weeks. Then, the chondrogenic and osteogenic constructs were sutured together with one layer of  
19  
20 highly concentrated and undifferentiated UCMSCs solution in the interface. The constructs were  
21  
22 cultured in DMEM low glucose supplemented with dexamethasone and IGF-1 for another 3  
23  
24 weeks. Two chondrogenic constructs, two osteogenic constructs, or one chondrogenic and one  
25  
26 osteogenic constructs were sutured (all the three groups without cells in the interface) and used  
27  
28 as controls. Results revealed that the chondrogenesis and osteogenesis of UCMSCs before  
29  
30 suturing were confirmed by the expression of Col II and Runx-2 related transcription factor 2  
31  
32 genes, respectively. Increased ECM secretion was observed during the co-culture. The  
33  
34 histological and immunohistochemical stainings (GAG, Col I and calcium) results showed that  
35  
36 the OC constructs with one layer undifferentiated cells in the interface presented better  
37  
38 integration and transition in the constructs as compared with the controls.  
39  
40  
41  
42  
43  
44  
45  
46  
47

48 Co-culture approach of BMSCs and osteoblasts was introduced for osteochondral interface  
49  
50 generation. Chen et al. seeded the rabbit BMSCs in silk scaffolds and placed the constructs in  
51  
52 chondrogenic medium for one week.<sup>48</sup> Meanwhile, rabbit osteoblasts were cultured in the cell  
53  
54 culture plate. Afterwards, the three-dimensional (3D) constructs and the two-dimensionally (2D)  
55  
56  
57  
58  
59  
60



1  
2  
3 cultured osteoblasts were co-cultured in chondrogenic medium for 3 weeks by contacting them  
4 together. Non-co-cultured 3D constructs were used as control. The results demonstrated that  
5 moderate downregulation of chondrogenic marker genes (such as Col II and Aggrecan) was  
6 observed in comparison with the control group. But the Sox-9 and Col I expressions increased.  
7  
8 Only the chondrogenic BMSCs layer in contact with the osteoblasts expressed OC interface  
9 markers, such as Col X and MMP-13, which were not observed in the control group.  
10  
11  
12  
13  
14  
15  
16

17 As these studies bring new insights into OC regeneration, further efforts on controlling the  
18 thickness and improving the strength of the interface should be considered.  
19  
20  
21  
22  
23

### 24 **In Vivo Studies on OC Tissue Engineering**

25  
26 After the in vitro biological performance examination, the biomaterials should be evaluated by  
27 the in vivo studies before going for the clinical trials. Compared with the simplified and  
28 optimized culture conditions of the in vitro study, the in vivo study provides more complex  
29 environments and thus closely mimics the real scenario of OC tissue. In the literature, it was  
30 found that rabbit was a popular animal model for creation of OCD.<sup>36</sup> Larger animal models were  
31 also used, such as pigs.<sup>49</sup> Subcutaneous implantation models were also used to screen ectopic  
32 formation of the tissues.<sup>50</sup> In OCD model, majority of the studies selected femoral condyles in  
33 the knee as the implantation sites. OCD created in patella groove or trochlear groove was also  
34 popular model. The in vivo studies offer important information for the selection of biocompatible  
35 materials, optimization of scaffold/hydrogel component or structure, determination of the release  
36 profiles of bioactive reagents, etc. The following will discuss several important aspects in the in  
37 vivo studies on OC regeneration.  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53

### 54 ***Materials intrinsic and structural properties***

1  
2  
3 The intrinsic and structural properties of biomaterials could affect the OC regeneration. The  
4  
5 intrinsic properties of biomaterials (such as the purity, chemical groups, molecular weight and  
6  
7 monomer ratio) are critical for the immune response of the host cells, the recruitment of the  
8  
9 reparative cells, and the formation of new tissues.  
10  
11

12  
13 Igarashi et al. combined rabbit autologous BMSCs with alginate gels of different grades for  
14  
15 the regeneration of rabbit patellar groove OCD for 4 and 12 weeks.<sup>51</sup> It was found that the ultra-  
16  
17 purified alginate group demonstrated better histological and mechanical outcomes compared  
18  
19 with commercial alginate groups. Freeze-dried chitosan scaffolds of different molecular weights  
20  
21 (349.3, 507.4, 510.6, 7.9, 10.3, and 11.49 kDa) and deacetylation degrees (91% and 83%) were  
22  
23 investigated by Abarategi et al. via implantation them in rabbit medial femoral condyle OCD  
24  
25 model for 3 months.<sup>52</sup> Better subchondral bone regeneration and noticeable cartilaginous tissue  
26  
27 regeneration were observed in chitosan scaffolds of intact mineral content, 83% deacetylation  
28  
29 degree and 11.49 kDa molecular weight in contrast with other groups. Jansen et al. compared  
30  
31 scaffolds prepared from copolymers comprised of varied poly(ethylene oxide terephthalate)  
32  
33 (PEOT) and poly(butylene terephthalate) (PBT) block ratios for OC regeneration in rabbit medial  
34  
35 femoral condyle for 12 weeks.<sup>53</sup> When PEOT/PBT was 70/30, the scaffolds mainly consisted of  
36  
37 cartilage-like tissue on top of the trabecular bone. While decreasing the PEOT/PBT ratio to  
38  
39 55/45, the scaffolds comprised mainly of cancellous bone.  
40  
41  
42  
43  
44  
45

46  
47 Structural properties of biomaterials also play important roles in their in vivo biological  
48  
49 performances for OC regeneration, such as porosity, pore size and format. Ikeda et al. compared  
50  
51 PLGA scaffolds of different porosities (80%, 85%, and 92%) by implantation the scaffolds in  
52  
53 rabbit patellar groove OCD for 6 and 12 weeks time periods.<sup>54</sup> It was found that, scaffolds of  
54  
55 85% and 92% porosities presented significant higher histological scores than the scaffolds of  
56  
57  
58  
59  
60

1  
2  
3 80% porosity at both time points. The higher porosity allowed better migration of the MSCs. On  
4  
5 the other hand, the pore size effect on OC regeneration was investigated by Duan et al.<sup>55</sup>  
6  
7 Bilayered PLGA scaffolds of the same porosity (85%) but with different pore sizes in the  
8  
9 chondral and bony layers (50-100  $\mu\text{m}$ , 100-200  $\mu\text{m}$ , 200-300  $\mu\text{m}$  and 300-450  $\mu\text{m}$ ) were  
10  
11 developed. The scaffolds were seeded with allogenic rabbit BMSCs and the constructs were  
12  
13 cultured for 7 days before implantation in rabbit femoral condyle for 6 and 12 weeks. They  
14  
15 found that pore size between 100-200  $\mu\text{m}$  was beneficial for chondral repair and the one between  
16  
17 300-450  $\mu\text{m}$  was good for bone regeneration. Hui et al. rehydrated the previously freeze-dried  
18  
19 OPF hydrogels and then implanted them in load-bearing regions of lateral and medial condyle  
20  
21 OCD in 8 months old pigs for 2 and 4 months.<sup>49</sup> It was found the scaffold induced neotissue  
22  
23 filling to 58% and 54% after 2 and 4 months, respectively. Newly formed hyaline cartilage made  
24  
25 up 39% of the neotissue after 4 months, but without inducing subchondral bone regeneration.  
26  
27  
28  
29  
30

31  
32 By analysis of the in vivo study results, we can select the most suitable component and the  
33  
34 best structure for further study.  
35  
36  
37

### 38 ***Bioactive scaffolds***

39  
40 Development of bioactive scaffolds without growth factors is an attractive approach for OC  
41  
42 regeneration due to the low cost and simple processing procedure. ECM based scaffold could be  
43  
44 a good choice for this purpose. ECM, which is produced by the host cells, contains bioactive  
45  
46 molecules for driving tissue regeneration and provides biomimetic microenvironments for  
47  
48 cellular homing. There were successful reports on ECM application in clinic, such as  
49  
50 cardiovascular and muscle.<sup>56, 57</sup> The ECM based scaffolds can be vitalized or devitalized tissues.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Emans et al. ectopically created cartilage tissue in periosteum by creating periosteal defects in the tibia of rabbits.<sup>58</sup> After 14 days, the reactive tissues were harvested and implanted in rabbit medial condyle OCD with and without hyaluronan for 3 weeks and 3 months time periods. Empty defects, defects filled with hyaluronan were used as controls. The results showed that empty defect and hyaluronan groups were far from fully filled, while ectopic cartilage groups with and without hyaluronan were filled to the level of the adjacent cartilage 3 weeks after implantation. After 3 months, empty defects were partially filled with fibrous or fibrocartilaginous tissue, but the ectopic cartilage implanted groups (with or without hyaluronan) were almost fully filled with both fibrocartilaginous and hyaline cartilage. The modified O'Driscoll scores for empty defect and hyaluronan groups were  $12.7 \pm 6.4$  and  $15.3 \pm 3.2$ , and the ectopic cartilage implanted defects without or with hyaluronan were  $15.4 \pm 3.9$  and  $18.2 \pm 2.9$ . Rabbit chondrocytes-derived ECM scaffolds were studied by Jin et al.<sup>25</sup> Rabbit chondrocytes were cultured for 3 weeks in pellet-type manner. The formed cartilage tissue were freeze-dried and used as scaffolds for culture of rabbit chondrocytes for varied time periods (2-day, 2-week and 4-week groups). The constructs were then applied in OC regeneration in rabbit patellar grooves for 1 and 3 months. Untreated defects were used as control. After 1 month, the 2-week and 4-week groups were repaired with hyaline cartilage like tissue, while fibrocartilage tissues were observed in the control and the 2-day groups. After 3 months, the 4-week group presented striking features of hyaline cartilage, with a mature matrix and a columnar arrangement of chondrocytes. This group also displayed prominently zonal distribution of Col II, the highest International Cartilage Repair Society score among all the groups, and well restored subchondral bone.


1  
2  
3 Decellularized OC tissue and non-OC tissues were also used for OC regeneration. Yagihashi  
4 et al. filled the rabbit patellar fossa OCD with decellularized bovine dentin matrix (50 or 100 mg  
5 per defect) for 1 to 9 weeks.<sup>59</sup> Untreated defects served as control. After 3 weeks, the 100 mg  
6 group had higher new bone formation compared with the other groups, but the difference  
7 decreased with time. The 100-mg group showed better cartilage regeneration compared with the  
8 other groups, with hyaline cartilage in the peripheral area after 6 weeks and hyaline cartilage  
9 with similar thickness to the normal one after 9 weeks. Yang et al. produced a bilayered scaffold  
10 consisting of a decellularized cartilage matrix layer (chondral part) and a decellularized  
11 cancellous bone matrix layer (bony part).<sup>60</sup> Canine BMSCs were chondrogenically differentiated  
12 for 14 days and then seeded onto the chondral part of the bilayered scaffolds. The constructs  
13 were implanted in canine bilateral femoral condyle for 3 and 6 months after in vitro culture for 4  
14 days. Scaffolds without cells were implanted as control. Results displayed that the macroscopic  
15 and histological grading scores of the experimental group were always higher than those of the  
16 control group. The scores for experimental group after 6 months showed higher values than those  
17 after 3 months. The stiffness of the neocartilage and subchondral bone in the experimental group  
18 was 70.77% and 74.95% of the ones of normal tissues, respectively. GAG content of the  
19 experimental group was 84.82% of the one of native cartilage. Regular and mature subchondral  
20 bone formed at both time points in the two groups.  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44

45 Successful decellularization procedure allows the application of allogeneic or xenogeneic  
46 ECM scaffolds for OC regeneration. However, the mechanical properties of the ECM derived  
47 scaffolds are normally lower than the ones of the original tissues, due to the decellularization  
48 process. Development of composite scaffolds consisting of ECM and other synthetic  
49 biomaterials may provide a solution to overcome this limitation.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### *Layered scaffolds*

Similar to the in vitro studies, layered scaffolds were investigated intensively for in vivo OC regeneration using acellular or cellular strategy.

In our recent study, bilayered Silk/Silk-NanoCaP scaffolds were developed and implanted in rabbit knee condyle OCD for 4 weeks in an acellular strategy.<sup>61</sup> Neocartilage formation in the chondral layer and abundant subchondral bone ingrowth in the bony layer of the bilayered scaffolds were observed (**Figure 2**). Jiang et al. developed bilayered poly(D-lactic acid) (PDLA) (chondral layer) and PDLA/tricalcium phosphate (bony layer) scaffolds. Autologous porcine chondrocytes were seeded into the chondral layer of the bilayered scaffolds and then the constructs were implanted by press-fit method in porcine medial/lateral femoral condyle OCD for 6 months.<sup>62</sup> Scaffolds without cells served as control. The results of the experimental group showed that the scaffold retained in the center and cancellous bone formed in the periphery of the osseous layer. In the chondral phase, hyaline cartilage regeneration was confirmed by the positive Col II and Safranin O staining. Only fibrous tissue formed in the scaffold alone group. Both groups supported subchondral bone regeneration and mineralization. Shao et al. incorporated allogenic rabbit BMSCs into bilayered PCL and PCL/tricalcium phosphate (TCP) scaffolds by using fibrin gel and then implanted the scaffolds in rabbit medial femoral condyle OCD for 3 and 6 months.<sup>63</sup> Scaffolds without cells were used as control. The experimental group displayed superior repair results as compared with the control group. Bone regeneration was good and consistent at both time points. After 3 months, all samples presented mixtures of neocartilage tissue and scaffold. After 6 months, some samples showed degradation while others presented normal cartilage appearance.



**Figure 2.** Silk based bilayered scaffold for OC regeneration in rabbit femur condyle after implantation for 4 weeks. (A) Macroscopic image of the bilayered scaffold. (B) Masson's trichrome staining of the explants. The black arrows indicate neocartilage formation in the silk layer and the white arrow indicates new subchondral bone formation inside the silk-nanoCaP. (C) Safranin O staining in the silk layer of the explants. It was revealed that abundant GAG and proteoglycan formed in the inner domain of the silk layer. Arrow indicates chondrocytes. (D) Masson's trichrome staining of the silk-nanoCaP layer in the explants. Arrow indicates new vessel formation. (E) Col II staining (fluorescent immunohistochemistry) in the silk layer of the explants. Arrow indicates Col II (red), while scaffold was stained blue. (F) SNA-lectin immunohistochemical staining for the endothelial cells invading the silk-nanoCaP layer. Arrow indicates vessels. "NB" indicates new bone inside the scaffold, "S" indicates scaffold. Adapted from Reference (61), with permission from Elsevier.

1  
2  
3 Multilayered scaffolds were also studied by in vivo models.<sup>50, 64, 65</sup> Tri-layered scaffold was  
4 generated by Tampieri et al., which contained an upper layer of collagen/hyaluronan, a lower  
5 layer of biomineralized collagen, and a intermediate layer of biomineralized collagen with lower  
6 extent of mineral.<sup>50</sup> The tri-layered structure of the scaffold mimicked the cartilage, tidemark and  
7 subchondral bone regions in OC tissue. Ewe BMSCs were seeded onto the scaffolds and the  
8 constructs were subcutaneously implanted in nude mice for 8 weeks. The results revealed that  
9 cartilaginous matrix deposition was observed only in the loose chondral layer, and bone tissue  
10 was only formed in the subchondral layer. In the study from Da et al., one compact PLGA/TCP  
11 layer was generated between the porous decellularized bovine cartilage ECM layer (chondral  
12 layer) and the porous PLGA/TCP layer (bony layer).<sup>64</sup> These scaffolds presented superior anti-  
13 tensile and anti-shear properties to the control scaffold without compact layer. Rabbit BMSCs  
14 after osteogenic or chondrogenic differentiation for 21 days were seeded onto the bony and  
15 chondral parts of the scaffolds, respectively. The constructs after 3 days culture in DMEM were  
16 implanted in OCD in rabbit patellofemoral groove for 3 and 6 months. Bilayered scaffolds  
17 without compact layer were used as control. The results showed that the higher macroscopic  
18 scores, GAG and collagen contents, as well as superior histological results were observed in the  
19 scaffolds containing compact layer compared with the control.  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44

### 45 ***Biological cues***

46 Biological cues have been introduced into the scaffolds for the purpose of enhancing  
47 chondrocyte proliferation, or guiding the progenitor cells to mature and subsequently form  
48 healthy OC tissues.  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 A representative method is the incorporation of growth factors in the scaffolds. Huang et al.  
4 combined the basic fibroblast growth factor (bFGF) in the poly(L-lactic acid)/amorphous  
5 calcium phosphate (ACP/PLLA) hybrid scaffolds and implanted these scaffolds in rabbit femoral  
6 condyle OCD for 4 and 12 weeks.<sup>66</sup> Untreated defects and PLLA scaffolds incorporated with  
7 bFGF were used as controls. The results showed that PLLA group presented better defect filling  
8 compared with untreated group. Mainly fibrocartilage and limited bone formation were observed  
9 in the PLLA scaffolds. Additionally, only a little amount of Col II and no aggrecan genes were  
10 measured for this group. In the case of ACP/PLLA group, most of the defects were filled with  
11 well-established cartilage tissue with large amount cartilaginous ECM. Positive Col II staining  
12 was observed, and high level of Col II and aggrecan genes were detected.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26

27 In order to control the release profile, growth factors could be loaded firstly into microspheres  
28 and then incorporated in the scaffolds for OC repair.<sup>67, 68</sup> In the study of Reyes et al., PLGA  
29 microsphere incorporating TGF- $\beta$ 1 or BMP-2 were loaded in the top alginate layer of the  
30 bilayered alginate/PLGA scaffolds.<sup>67</sup> The bilayered scaffolds with 2.5  $\mu$ g or 5  $\mu$ g BMP-2, or 50  
31 ng TGF- $\beta$ 1 in the alginate layer were implanted in rabbit medial condyle OCD for 2, 6, 12 and  
32 24 weeks. Empty defects and unloaded scaffolds served as controls. After 6 weeks, all growth  
33 factor-treated groups displayed clear signs of defect repair, with complete repair of subchondral  
34 bone and good quality cartilage in most of the cases. In week 12, remarkably regeneration  
35 improvements in cartilage were observed between the untreated and growth factor-treated  
36 specimens, especially with TGF- $\beta$ 1 and 5  $\mu$ g BMP-2 groups. All the growth factor-treated  
37 groups exhibited typical hyaline cartilage and regular surface in the defects. The results in week  
38 24 were similar with the ones in week 12. Kim et al. combined IGF-1 and/or TGF- $\beta$ 3 loaded  
39 gelatin microparticles in the chondral layer of the bilayered OPF hydrogels.<sup>69</sup> The chondral OPF  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 layer was 1 mm in thickness. Four groups of hydrogels were developed: Control without growth  
4 factor; microparticles loaded IGF-1; microparticle loaded IGF-1 and gel-loaded TGF- $\beta$ 3;  
5 microparticles-loaded IGF-1 and microparticles-loaded TGF- $\beta$ 3. The bilayered hydrogels were  
6  
7  
8 implanted in rabbit medial femoral condyles for 12 weeks. The results revealed that all the  
9  
10 groups showed improvement in cartilage morphology compared with the control. Single delivery  
11  
12 of IGF-1 displayed higher scores in subchondral bone morphology, improved chondrocytes and  
13  
14 GAG amounts in adjacent cartilage tissue when compared with a dual delivery of IGF-1 and  
15  
16 TGF- $\beta$ 3.  
17  
18  
19  
20  
21

22 Gradient growth factors loading strategy was applied for in vivo OC interface regeneration.<sup>70,</sup>  
23  
24 <sup>71</sup> Mohan et al. developed PLGA microsphere based scaffolds with continuous gradients in the  
25  
26 loaded growth factors and material composition.<sup>71</sup> The scaffold was composed of a chondral  
27  
28 layer of TGF- $\beta$ 1 loaded PLGA microspheres, a bony layer of BMP-2 loaded PLGA or  
29  
30 PLGA/HA microspheres, and a gradient transition of the two layers in the middle. Blank PLGA  
31  
32 scaffolds and blank gradient PLGA and PLGA/HA scaffolds (without growth factors) were used  
33  
34 as controls. The four groups of scaffolds were implanted in rabbit medial condyle OCD for 6 and  
35  
36  
37  
38 12 weeks. The gross morphology, MRI and histology data showed that the greatest extent of  
39  
40 regeneration of cartilage and subchondral bone were achieved by the gradient PLGA and  
41  
42 PLGA/HA scaffolds with growth factors loading. This group presented similar GAG content and  
43  
44 cartilage thickness to the ones of the native cartilage, as well as higher bone filling and better  
45  
46 edge integration with host bone compared with the other groups.  
47  
48  
49

50 The platelet-rich plasma (PRP) contains a pool of growth factors and is considered as a  
51  
52 promising alternative to commercial growth factors.<sup>72-74</sup> Comparison of the PRP scaffolds seeded  
53  
54 with BMSCs or ADSCs for OC regeneration was performed by Xie et al.<sup>73</sup> The cells suspension  
55  
56  
57  
58  
59  
60

1  
2  
3 was mixed with PRP first and then the PRP would formed a fibrin clot by the activation of  
4 calcium from the medium. The BMSCs/PRP or ADSCs/PRP constructs were cultured in vitro for  
5  
6  
7  
8 3 weeks and also implanted in male rabbit patellar groove OCD for 6, 9 and 12 weeks. PRP  
9  
10 alone and untreated defects served as controls. The in vitro results showed that the BMSCs  
11  
12 constructs exhibited higher proliferation rate, enhanced expressions of cartilage-specific genes  
13  
14 and proteins compared with the ADSCs constructs. Regarding the in vivo study outcomes, the  
15  
16 BMSCs seeded scaffolds displayed better gross appearance, histological and  
17  
18 immunohistochemical characteristics, higher cartilage-specific genes and protein expressions,  
19  
20 and superior subchondral bone regeneration compared with the other groups. This study has thus  
21  
22 shown that PRP constructs can induce the differentiation of the seeded ASC into functional  
23  
24 chondrocytes in vivo.  
25  
26  
27  
28

29  
30 Apart from the growth factors, gene delivery was also employed for OC regeneration. Chen et  
31  
32 al. generated a plasmid TGF- $\beta$ 1 containing chitosan-gelatin scaffold as chondral part and a  
33  
34 plasmid BMP-2 loaded HA/chitosan-gelatin scaffold as subchondral bone part.<sup>75</sup> Rabbit BMSCs  
35  
36 were seeded onto the chondral or the osteochondral bone part and the constructs were separately  
37  
38 cultured for one week. Afterwards, a bilayered gene-activated scaffold was generated by  
39  
40 combining the chondral and subchondral bone constructs with fibrin gel and subsequently the  
41  
42 bilayered constructs were cultured in vitro for two weeks. The bilayered constructs were then  
43  
44 implanted in rabbit patellar groove OCD for 4, 8 and 12 weeks. Scaffolds without plasmids,  
45  
46 mono layer scaffolds with TGF- $\beta$ 1 or BMP-2 gene were also implanted. Empty defects were  
47  
48 used as control. The in vitro result showed that high level of TGF- $\beta$ 1 and BMP-2 protein  
49  
50 secretions by the seeded BMSCs were observed in the chondral layer and the subchondral layer,  
51  
52 respectively. Regarding the in vivo outcomes, the monolayer scaffolds with BMP-2 gene  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 presented complete trabecular bone ingrowth within subchondral bone region and good  
4  
5 integration with native bone tissue, but abundant Col I in the cartilage part. The monolayer  
6  
7 scaffolds with TGF- $\beta$ 1 gene showed similar cartilage surface with native cartilage, while the  
8  
9 regeneration of subchondral bone was insufficient. The bilayered scaffolds incorporated with  
10  
11 genes simultaneously supported the regeneration of articular cartilage and subchondral bone  
12  
13 under a spatially controlled manner after implantation for 12 weeks.  
14  
15

16  
17 In OC regeneration, the terminal differentiation of BMSCs often brings adverse outcomes. To  
18  
19 address this issue, intra-articular injection of parathyroid hormone-related protein (PTHrP)  
20  
21 together with implantation of bilayered collagen (chondral layer) and silk-HA (bony layer)  
22  
23 scaffolds in rabbit patellar groove OCD for 16 weeks was performed by Zhang et al.<sup>76</sup> The  
24  
25 injection of PTHrP was carried out at three time windows (4-6, 7-9, and 10-12 weeks) every 7  
26  
27 days after implantation. PBS was injected as control. It was found that defects treated with  
28  
29 PTHrP at the 4-6 weeks time window exhibited better regeneration (reconstitution of cartilage  
30  
31 and subchondral bone), minimal terminal differentiation (hypertrophy, ossification and matrix  
32  
33 degradation), as well as enhanced chondrogenesis (cell shape, collagen II, and GAG content),  
34  
35 compared with treatments at other time windows and control. The timing also influenced PTHrP  
36  
37 receptor expression.  
38  
39  
40  
41  
42

43  
44 In the future, clinically relevant doses of growth factors or other bioactive factors and  
45  
46 possibilities for their controlled release for OC regeneration should be further investigated.  
47  
48

### 49 50 ***Gene transfection***

51  
52 The incorporation of bioactive factors in scaffolds for OC regeneration is subject to many  
53  
54 complicated aspects, such as carrier properties, encapsulation efficiency and shelf life of the  
55  
56  
57  
58  
59  
60

1  
2  
3 drugs. Production of these active factors by the cells is an attractive method. For this purpose, the  
4  
5 gene transfer technology has been used for OC regeneration.<sup>75, 77-84</sup>  
6  
7

8 Ueblacker et al. performed the transfection of rabbit chondrocytes with lacZ gene which was  
9  
10 fused with tetracycline-responsible element (TRE).<sup>84</sup> The gene expression of the transfected cells  
11  
12 was controlled by the non-toxic drug, such as tetracycline or doxycycline. The transfected cells  
13  
14 were seeded into collagen sponges and subsequently implanted in the rabbit femur patellar  
15  
16 groove OCD for 4 weeks. The lacZ gene expression can be detected for 3 weeks with  
17  
18 doxycycline treatment. The implants were integrated well with the host tissue. This study  
19  
20 provided new insights for regulation of gene expression for OCD treatment.  
21  
22  
23

24 Producing growth factors by engineered cells has been studied. Chen et al. transduced de-  
25  
26 differentiated rabbit chondrocytes with recombinant baculovirus expressing BMP-2 and seeded  
27  
28 the engineered cells onto PGA scaffolds.<sup>77</sup> The scaffolds were cultured in a rotating bioreactor  
29  
30 for 0, 1 and 3 weeks. The constructs were then implanted into rabbit knee patellar groove OCD  
31  
32 for 8 weeks. Mock-transduced constructs without bioreactor culture were implanted as control.  
33  
34 In vitro results showed that increased time led to more mature cartilaginous constructs.  
35  
36 Regarding the in vivo results, the control group did not showed any repair of the defect. The 0  
37  
38 week constructs (without bioreactor culture) resulted in incomplete regeneration of the defect.  
39  
40 The 1 week constructs presented neocartilage layer rich in GAG and Col II, while non-complete  
41  
42 integration between the graft and host cartilage. The 3 week constructs displayed regeneration of  
43  
44 hyaline cartilage, improved integration, Col II and GAG rich matrixes. Madry et al. transfected  
45  
46 the lacZ gene (control) and human IGF-I cDNA to allogenic lapine articular chondrocytes.<sup>83</sup> The  
47  
48 cells were cultured in PGA scaffolds in a rotating bioreactor for 10 or 28 days. The constructs  
49  
50 were then implanted into OCD of rabbit knee patellar groove for 28 weeks. It was found that  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 engineered cartilage with genetically modified chondrocytes (overexpressing human IGF-I)  
4  
5 markedly enhance the repair of OCD compared with the control group. The longer in vitro  
6  
7 culture time led to superior OC regeneration outcomes and resulted in significantly decreased  
8  
9 osteoarthritic changes in the neighboring tissue of the defects. In the future, more investigations  
10  
11 on the optimization of introduced genes, improvement of transfection efficiency, and modulation  
12  
13 of the transfected gene expression should be performed.  
14  
15  
16  
17  
18  
19

### 20 *External stimulus*

21  
22 Besides the scaffolds, cells and biological cues, the external stimulus (such as mechanical  
23  
24 stimulus) is also important for the healing of OC tissues.<sup>85, 86</sup> Chang et al. implanted acellular  
25  
26 PLGA scaffolds in rabbit femoral condyle OCD for 4 and 12 weeks. Immobilization (Imm),  
27  
28 intermittent active motion (IAM), and continued positive motion (CPM) treatments were  
29  
30 performed on the rabbits in the day following the surgery.<sup>93</sup> Empty defects were used as control.  
31  
32 After 12 weeks, the CPM group presented the best outcome with normal articular surfaces and  
33  
34 no contracture in the joint. While Imm and IAM groups showed degenerated joints, abrasion  
35  
36 cartilage surface and synovitis. The CPM group also showed significantly higher bone volume  
37  
38 compared with the other groups. These results implied that the post-surgery physical stimulus  
39  
40 synergistically contributed to the healing of OCD. Other external physical treatments are worthy  
41  
42 to be explored in OC tissue engineering, such as electrical and magnetic stimuli, acupuncture and  
43  
44 so on.  
45  
46  
47  
48  
49  
50  
51  
52

### 53 **Clinical Studies on OC Tissue Engineering**

54  
55  
56  
57  
58  
59  
60

**Table 1.** Clinical Studies on OC Tissue Engineering

Scaffolds/Cells	Defect site Follow up time Patient number Type of study	<ul style="list-style-type: none"> <li>● Success rate</li> <li>▲ Advantages</li> <li>▼ Disadvantages</li> </ul>	Ref
Hyalograft C® scaffold with human autologous chondrocytes (MACI)	Ankle 12 and 36 months 46 Prospective	<ul style="list-style-type: none"> <li>● The preoperative AOFAS score was 57.2±14.3. After 12 and 36 months, the scores were 86.8±13.4 and 89.5±13.4, respectively.</li> <li>▲ The histological staining (blinded analysis) revealed that hyaline-like cartilage was formed.</li> </ul>	20
Biphasic collagenous scaffold with autologous chondrocytes (MACI)	Knee 6 and 12 months 30 Prospective	<ul style="list-style-type: none"> <li>● The IKDC scores increased from 24 to 44 and 66 after 6 months and 1 year post-operation, respectively. The MOCART score (blinded analysis) was improved from 11.5 (6 months) to 13 (1 year).</li> <li>▲ Good clinical results were achieved even when MACI as a second-line procedure.</li> </ul>	87
Col I/III bilayered membrane with autologous chondrocytes (MACI)	Ankle 1 and 2 years 10 Prospective	<ul style="list-style-type: none"> <li>● The AOFAS scores increased from 61.2 (preoperative, ranged from 42-76) to 74.7 (1 year postoperative, ranged from 46-87) and 73.3 (2 year postoperative, ranged from 42-90).</li> <li>▲ MACI may be an effective treatment for full-thickness lesions in talus without malleolar osteotomy.</li> </ul>	89
Porcine Col I scaffold with autologous chondrocytes (MACI)	Ankle Mean 24.5 months 18 Prospective	<ul style="list-style-type: none"> <li>● For AOFAS score, 64% were rated as excellent/good, whereas 36% were rated fair/poor. The FFI pain and disability, AOFAS, AAOS scores were 5.5 ± 2.0, 5.0 ± 2.3, 58.6 ± 16.1 and 59.9 ± 16.0 before MACI. After MACI, these scores were 28 ± 2.2, 2.6 ± 2.2, 80.4 ± 14.1 and 83.5 ± 13.2, respectively. MOCART score (blinded analysis) was 62.4±15.8.</li> <li>▲ MACI is a safe procedure for the treatment of OCD in the ankle.</li> </ul>	90
Type I/III Col membrane with autologous chondrocytes (MACI)	Knee 1 year 5 Prospective	<ul style="list-style-type: none"> <li>▲ Pain reduction and significant improvement in function were observed after the MACI.</li> </ul>	85

Table 1. Continued (1)

Scaffold/Cell	Defect site Follow up Time Patient number Type of study	<ul style="list-style-type: none"> <li>● Success rate</li> <li>▲ Advantages</li> <li>▼ Disadvantages</li> </ul>	Ref
Col powder or hyaluronan membrane loaded with concentrated BMSCs (MASI)	Ankle 6, 12, 18 and 24 months 23 (Col) 25 (Hyaluronan) Prospective	<ul style="list-style-type: none"> <li>● In Col group, the AOFAS score was 62.5±18 pre-operation and increased to 89.8±9.8, 24 months post-operation. In the hyaluronan group, the scores increased from 66.2±10.5 to 92.8±5.3, 24 months post-operation.</li> <li>▲ One-step procedure using concentrated BMSCs, scaffolds and platelet gel for OCD treatment. MRI showed restoration in cartilage and subchondral bone after 2 years.</li> </ul>	24
Trufit®	Patella 6 to 24 months 10 Prospective	<ul style="list-style-type: none"> <li>● After one year follow-up, the results were satisfactory in 80% patients.</li> <li>▲ One-step procedure for OCD treatment.</li> <li>▼ After 18 months follow up, 9 patients suffered pain and knee swelling. Reoperation rate for implant failure reached 70%. MRI screened at final follow up showed a cylindrical cavity of fibrous tissue instead of subchondral bone ingrowth.</li> </ul>	21
Multilayered scaffold contains PLGA, PGA, and calcium sulphate (Trufit BGS® plug)	Knee 6-39 months 26	<ul style="list-style-type: none"> <li>▲ The plug demonstrated flush morphology at early (<math>\leq 6</math> months) and longer follow-up (<math>\geq 16</math> months), T2 relaxation times of the plug approached those of normal articular cartilage at longer follow up.</li> <li>▼ The plug presented deteriorated appearance at ~12 months follow-up.</li> </ul>	88
Trufit BGS® plug	Knee (donor sites after subchondral transplantation) 2-63 months 9	<ul style="list-style-type: none"> <li>● Post-operation, the CT scan showed decrease in the House Units from 84 (4 months) to 19 (13 months). The ossification quality score was 1 (soft-tissue density) instead of 4 (cancellous bone).</li> <li>▼ No evidence of bone ingrowth, ossification or osteoconductivity. The density of the donor sites declined over time.</li> </ul>	91
Trufit® plug	Knee 6 and 12 months 20 Prospective	<ul style="list-style-type: none"> <li>▲ The short-term clinical and MRI results were modest. No deterioration of the repaired tissue was observed.</li> <li>▼ 3 of the 15 patients failed and had to undergo autologous OC transplantation.</li> </ul>	94



Table 1. Continued (2)

Scaffold/Cell	Defect site Follow up Time Patient number Type of study	<ul style="list-style-type: none"> <li>● Success rate</li> <li>▲ Advantages</li> <li>▼ Disadvantages</li> </ul>	Ref
Multilayered nano-composite scaffold containing Col and Col/HA scaffold (MaioRegen®)	Knee 6 months 13 (15 defects) Prospective	<ul style="list-style-type: none"> <li>● 4-5 weeks post-operation, 86.7% lesions were of completely attached graft and repair tissue. Complete filling of the cartilage defect and congruency of the articular surface were seen in 10 defects after 6 months. 13.3% detachment was observed.</li> <li>▲ Histological analysis showed the formation of subchondral bone without the presence of materials.</li> <li>▼ Oedema or sclerosis in subchondral bone was presented in 8 defects.</li> </ul>	22
MaioRegen®	Knee 6, 12, and 24 months 30 Prospective	<ul style="list-style-type: none"> <li>● IKDC objective score changed from 50.0% (preoperation) to 96.4% and 85.7% at 12 and 24 months follow up, respectively. The mean Tegner score was 1.6±1.1 preoperative, 4.0±1.6, and 4.0±1.8 at the 12 months and after 2 years follow up. Complete filling of the cartilage and integration of the graft were observed in 70% of the lesions.</li> <li>▼ Only 7% of the subchondral lamina and 47% of the bone were considered intact.</li> </ul>	92
MaioRegen® and HYAFF® -11	Knee 2-3 years 8(MaioRegen®) 7(HYAFF®-11)	<ul style="list-style-type: none"> <li>● When MaioRegen® was used, the IKDC score improved from around 40 (preoperation) to around 80 (postoperation). The Tegner score also increased significantly after the implantation. In case of HYAFF® -11, both the IKDC and Tegner scores were significantly improved.</li> </ul>	95
Bilayered PLGA/PLGA-TCP scaffolds with a chamber between the two layers loading autologous chondrocytes	Knee 3, 6, 12, and 24 months 10 Prospective	<ul style="list-style-type: none"> <li>● Postoperative KOOS in “symptoms” only significantly higher than the pre-operative value after 24 months. Whereas the other four subscales of KOOS were significantly higher than pre-operation values after 12 and 24 months.</li> <li>▲ Defects were completely filled and regenerated cartilaginous surfaces flushed with surrounding native joint surface. The regenerated cartilage appeared hyaline.</li> </ul>	96

1  
2  
3 Tissue engineering approaches have already shown its charm in clinical OC regeneration. **Table**  
4  
5 **1** summarized the clinical studies on OC tissue engineering.<sup>20-22, 24, 87-96</sup> These approaches include  
6  
7  
8 MACI, matrix-associated stem cell implantation (MASI) and layered scaffold implantation.  
9

### 10 *MACI and MASI*

11  
12 MACI is the first application of tissue engineering for OC regeneration.<sup>97</sup> For this procedure,  
13  
14 autologous chondrocytes are combined with scaffolds first and subsequently implanted into the  
15  
16 defects. Collagen and hyaluronic acid scaffolds have been widely used in MACI. These materials  
17  
18 are superior regarding their biodegradation, biocompatibility and low immune response.  
19  
20  
21 However, they are disadvantageous for the weak mechanical properties.  
22  
23

24  
25 Comparing with ACI, MACI is advantageous in minimizing the donor site and getting rid of  
26  
27 periosteal harvesting and suturing. Some clinical studies showed that MACI is an efficient  
28  
29 method for OCD treatments, both in ankle and knee lesions.<sup>20, 87</sup> Giannini et al. showed that the  
30  
31 hyaluronan scaffold and specifically designed instrumentation allowed arthroscopic implantation  
32  
33 of chondrocytes in the ankle.<sup>20</sup> In a study from Giza et al, MRI images (blinded analysis) showed  
34  
35 the regeneration of articular cartilage and subchondral bone in a 19-months follow up after  
36  
37 MACI using the collagen scaffolds.<sup>89</sup> Even though there are many successful cases on MACI, the  
38  
39 clinical results of this approach are significantly related with the quality of chondrocytes used  
40  
41 and the patients' conditions. Normally, the cells harvested in this method are of low yield and  
42  
43 present limited long-term survival and regenerative capacity, specifically those from the elder  
44  
45 patients.<sup>98</sup> Pietschmann et al. reported that the morphologically abnormal cells led to the poor  
46  
47 clinical outcome in MACI.<sup>87</sup> Aurich et al. also mentioned that the age of the patient and the  
48  
49 duration of symptoms had significant impacts on the clinical outcomes.<sup>90</sup> Similar to ACI  
50  
51 procedure, MACI also requires the harvesting of chondrocytes from cartilaginous tissue which  
52  
53  
54  
55  
56  
57  
58  
59  
60


1  
2  
3 would induce secondary morbidity and increase the cost. Considering the limitation of  
4 autologous chondrocytes, other cell sources might be used as alternative, such as stem cells.  
5  
6

7  
8 MASI has been explored as an alternative to MACI. In this method, the autologous  
9 chondrocytes are replaced by autologous stem cells, e.g. BMSCs or ADSCs.<sup>98</sup> This new  
10 technology requires only a single operation and minimizes the invasion. Nejadnik et al.  
11 compared the clinical outcomes of autologous chondrocyte and BMSCs for cartilage  
12 regeneration (observational cohort study), and found that there were no differences in the two  
13 groups.<sup>99</sup> Interestingly, they also found that the younger patients showed better outcomes in the  
14 ACI group, while the age did not make differences in the BMSCs group. Scaffolds seeded with  
15 concentrated bone marrow-derived cells were also investigated for OC regeneration in clinical  
16 trials.<sup>24</sup> In another study, Kon et al. confirmed that the one-step bone marrow derived cell  
17 transplantation technology achieved good clinical and radiographic outcomes for patients with  
18 osteochondritis dissecans.<sup>95</sup> Besides BMSCs and ADSCs, there are also other stem cells which  
19 are worthy to be explored, such as stem cells from synovium, muscle, amnionic fluid, umbilical  
20 cord blood, Wharton jelly and so on.  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40

### 41 *Layered scaffolds*

42  
43 The MACI and MASI approach focus on the regeneration of cartilage layer in OCD, and indeed  
44 they have demonstrated effectiveness for this purpose. While recent 5-year MRI follow-up  
45 showed that subchondral bone diseases (such as edema, cysts, sclerosis, and granulation) were  
46 observed in 50% of the patients who underwent MACI.<sup>3</sup> This addresses the need for regeneration  
47 of subchondral bone together with the regeneration of cartilage layer in OC healing. Layered  
48 scaffolds, which mimics the structure and matrix component of OC tissue, provides a promising  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

option to overcome this problem.<sup>26</sup> The implantation of layered scaffolds in OCD only requires one surgery and no need for fixation.



**Figure 3.** Biomimetic osteochondral scaffolds for clinical application (MaioRegen®). (A) Scaffolds morphology and components. (B-D) Images showing the surgical procedure: (B) cutting the scaffold, (C) the scaffold is templated using an aluminum foil to obtain the exact size of the graft needed, (D) implantation of the scaffold using a press-fit technique. Adapted from References (12) and (22), with permissions from SAGE and Elsevier, respectively.

Currently, there are three artificial cell-free layered scaffolds available for clinical implantation in OCD: Trufit® CB plug, MaioRegen®, and Chondromimetic®. Trufit® CB plug is a cylindrical porous scaffold containing poly(lactic-co-glycolic acid) (PLGA), poly(glycolic acid) fiber and calcium sulfate. It is a press-fit implant, with tunable length and diameter ranging from

1  
2  
3 5 to 11 mm.<sup>88</sup> MaioRegen® is a biomimetic three layer scaffold (**Figure 3**). The composition  
4 from the top layer to the bottom layer resembles the contents of collagen and hydroxyapatite in  
5 the cartilage, tidemark and the subchondral bone, respectively.<sup>22</sup> Chondromimetic® is bilayered  
6 porous implant containing collagen, glycosaminoglycan, and calcium phosphate.<sup>100</sup> There are no  
7 clinical reports on this product yet. Comparing these three scaffolds, Trufit® CB plug composed  
8 of synthetic polymers may exhibit better mechanical properties than the other two scaffolds  
9 which mainly contain natural macromolecules. Good mechanical properties allow easy  
10 implantation and fixation of the scaffolds. On the other hand, the MaioRegen® and  
11 Chondromimetic® may display superior biocompatibility to Trufit® in terms of their  
12 degradation products and ability to guide cells' differentiation. Table 1 listed the clinical  
13 outcomes of Trufit® and MaioRegen®. Both satisfactory and negative results were achieved.  
14 These varied clinical outcomes of the layered scaffolds may be related to the patients' conditions  
15 (e.g., age, the site of lesion, the type and history of injury) and the intrinsic properties of the  
16 biomaterials. More evidences and further comparative studies are required to understand and  
17 relate all these aspects.

18  
19  
20 Attempt combining layered scaffolds and autologous chondrocytes was performed by Chiang  
21 et al.<sup>96</sup> Besides the healing of cartilage, it was also found that cancellous bone formed in the  
22 osseous phase without pre-seeding of cells. The biphasic scaffolds seeded with therapeutic  
23 autologous cells could be promising strategy for the treatment of OCD in the following. Specific  
24 cells might be loaded onto the corresponding layers, respectively. In order to circumvent the  
25 limitation of chondrocytes, cells derived from other sources could be used, e.g. ADSCs and  
26 BMSCs.

## Challenges and Future Perspectives in OC Tissue Engineering

Based on the amount of information gathered over the last few years while searching for effective strategies for OC regeneration, it is possible to comprehend the degree of complexity of this task and its limitations (**Scheme 1**).

OC Tissue Engineering		
	Strategies	Challenges
Clinical strategies	MACI	Two operations; fixation problem; donor site morbidity; non-sufficient subchondral bone regeneration.
	MASI	Multi-steps on blood and bone marrow collection, platelet gel formation, and bone marrow concentration; Fixation problem; non-sufficient subchondral bone regeneration.
	Layered scaffold without cells	Clinical results are preliminary; the influence of scaffold properties on long-term regeneration outcomes needs to be validated.
	Combination of MACI and layered scaffold	Donor site morbidity; clinical results are preliminary; the long-term regeneration outcomes and influence of scaffold properties need to be validated.
Pre-clinical strategies	Single layer or layered scaffold alone	Interaction between OCD regeneration outcomes and scaffolds properties (morphology, component, degradation...) or external stimulus (mechanical, chemical...) still needs to be elucidated.
	Single layer or layered scaffold with cells	The influence of scaffolds properties (morphology, chemical components...) on the cells phenotype or differentiation is not fully understood; controlling the cell fate is still a substantial hindrance.
	Single layer or layered scaffold with GF/Bioactive agents alone or GF/Bioactive agents and cells	The incorporation dose and release profile of GF/Bioactive agents need to be optimized; The long-term cells fate and regeneration outcome need to be validated.

**Scheme 1.** Current tissue engineering strategies and challenges for OC regeneration. For pre-clinical strategies, “scaffold” indicated porous scaffold or hydrogels with single layer or layered structure.


In the future, the development of novel bioactive and biomimetic scaffolds for OC regeneration will remain a major issue. The ideal scaffold are those which can be easily integrated with host tissue and include signals to guide the proliferation and differentiation of specific cells to form normal stratified OC tissue. In order to provide a satisfactory environment for the fast formation of OC tissue, the components in the chondral and the subchondral layers of the scaffold should

1  
2  
3 resemble the ones in the counterpart of the OC tissue. Additionally, it is important that the  
4 structure and components of the scaffolds favor the continuous and integrated OC interface  
5 generation. Moreover, the scaffold must maintain its structural integrity when implanted and  
6 present a degradation profile matching the growth pace of the de novo tissues. During the  
7 regeneration, the scaffolds should be capable of preventing the invasion of synovial fluid to the  
8 subchondral bone and the vascularization in the chondral layer.  
9

10  
11 To address these challenges, ECM-based biomaterials or synthetic ECM analogues are  
12 suitable components for scaffold preparation. In order to modulate the mechanical properties and  
13 degradation behavior of the scaffolds, controlling the conformations or the assembly process of  
14 biomacromolecules, introduction of degradable polymer as a reinforcing phase and regulation of  
15 the component ratios, are promising approaches. For the purpose of creating stratified and  
16 integrated OC tissue, layered scaffold with gradient transition in the varied phases is the optimal  
17 choice. Advanced processing methods are required to spatially control the structure and  
18 compositions in the scaffolds, specifically in the interface region.  
19

20  
21 Since OCD is varied in each individual patient, the customized design of the scaffolds for  
22 patients is of great demand. For the generation of customized OC grafts in the in vitro system,  
23 please see previous review from Grayson et al.<sup>17</sup> Nowadays, the computer-aided design and  
24 computer aided manufacture (CAD/CAM) technologies provide possibility to built scaffolds for  
25 specific individuals, no matter the shape and size of the defects (**Figure 4**).<sup>101, 102</sup> In the  
26 following, these techniques should be used for the preparation of scaffolds from various  
27 materials (or composite), and even including bioactive factors and/or stem cells for clinical  
28 application. Before being transferred to the clinic, there are still many problems which should be  
29 solved, such as optimization of the clinically related incorporation dose and release profile of the  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

bioactive factors, harnessing the fate of stem cells in vivo and guiding them precisely towards OC differentiation. Furthermore, the application technique of the scaffold should be taken into



**Figure 4.** Fabrication of customized biphasic scaffolds using CAD/CAM technology. The morphological information of the goat femoral head (A) was captured by laser scanning. The 3D data were reconstructed via the CAD software (B, C). PCL/HA scaffold (D, E) fabricated by fused deposition modeling (FDM) was designed to be with an intramedullary stem and interconnecting microchannels (H). The PGA/PLA scaffold (F) with relatively small pore size (I) was pressed into a hemispherical shape. The well-matched PGA/PLA scaffold and PCL/HA




1  
2  
3 scaffold formed a biphasic scaffold (G). Adapted from Reference (101), with permission from  
4  
5 Elsevier.  
6  
7

8  
9  
10 consideration, since non-invasive techniques (preferred by surgeons nowadays) imply  
11  
12 dimensional constrains to the materials.  
13  
14

15 The selection of proper cells for OC regeneration constitutes another critical issue. Adult  
16  
17 chondrocytes possess limited regenerative capacity and often undergo dedifferentiation. Adult  
18  
19 stem cells are attractive cell sources, while still require invasive harvesting process and are  
20  
21 associated with quality instability and low quantity. Other immature stem cells (such as AFSC  
22  
23 and UCMSCs) present superior activity and differentiation ability as compared to adult stem  
24  
25 cells, but there is a limited access to these cells. Embryonic stem cells (ESCs) possess unlimited  
26  
27 differentiation capacity and have been used for cartilage regeneration.<sup>103</sup> However, their  
28  
29 application is still under ethical argument.  
30  
31  
32  
33

34 Recently, induced pluripotent stem cells (iPSCs), as an alternative to ESCs, have been  
35  
36 investigated intensively.<sup>104</sup> Different from the ESCs, iPSCs can be created from somatic cells  
37  
38 and thus circumvent the ethical controversy of ESCs. The utility of iPSCs cells for OC  
39  
40 regeneration is promising. Ko et al. at first compared the in vitro chondrogenic differentiation  
41  
42 differences of human iPSCs (hiPSCs) and human BMSCs, and then applied the alginate gels  
43  
44 encapsulating hiPSCs pellet or hiPSCs for OCD regeneration in the patellar groove of  
45  
46 immunosuppressed rat for 12 weeks (**Figure 5**).<sup>105</sup> Empty defects and defects filled alginate gels  
47  
48 were used as controls. After in vitro culture for 21 days, the chondrogenic hiPSCs showed  
49  
50 greater GAG contents and superior chondrocytic characteristics, significantly lower level of Col  
51  
52 X and Col I compared with the chondro-induced BMSCs. Defects filled by alginate gels  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 incorporated with chondro-induced hiPSCs showed better cartilage regeneration than the empty  
4 defects or alginate alone group. For the next stage, more in vitro and in vivo studies should be  
5 defects or alginate alone group. For the next stage, more in vitro and in vivo studies should be  
6 conducted to compare the OC regeneration capacity between iPSCs and other adult stem cells,  
7 aiming to better understand the potential and control the differentiation of the iPSCs. For the  
8 optimization of the in vitro culture conditions, bioreactors might be used to provide consistent  
9 and adjusted environments.  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19



**Figure 5.** The application of human induced pluripotent stem cells (hiPSCs) for OC regeneration. (A) Safranin O staining of chondro-induced hiPSCs and human BMSCs (pellets and in alginate hydrogel) after 21 days. (B) In vivo repair of patellar OCD in immunosuppressed

1  
2  
3 rat after the implantation of chondro-induced hiPSCs for 12 weeks. Safranin O staining  
4 confirmed the cartilage regeneration in the hiPSCs containing groups. Adapted from Reference  
5  
6 (105), with permission from Elsevier.  
7  
8  
9

## 10 11 12 13 **Conclusions**

14  
15  
16 During the past few years, numerous advances have been achieved in OC tissue engineering.  
17  
18 Tissue engineering strategies, despite introducing more complexity and details to the current  
19  
20 treatments, present a high potential for OC regeneration. In fact, OC regeneration is an  
21  
22 interdisciplinary topic and integrative strategy should be employed. High-throughput approaches  
23  
24 may be applied in rapid materials screening, molecule tailoring, component combinations and  
25  
26 structure optimizations for scaffold design. It would be helpful to create novel in vitro culture  
27  
28 models (such as using bioreactors) and in vivo animal models which closely mimic the OC  
29  
30 microenvironment of the patients, and then test different constructs in these systems and thus  
31  
32 establish relationship of these results for guiding the clinical treatment. Although there are still  
33  
34 many critical problems to be solved, tissue engineering still represents the most promising  
35  
36 alternative for OC regeneration.  
37  
38  
39  
40  
41  
42  
43  
44

## 45 **Acknowledgements**

46  
47 The authors thank Portuguese Foundation for Science and Technology (FCT) through the  
48  
49 projects TISSUE2TISSUE (PTDC/CTM/105703/2008) and OsteoCart (PTDC/CTM-  
50  
51 BPC/115977/2009). We also acknowledge European Union's Seventh Framework Programme  
52  
53 (FP7/2007-2013) under grant agreement n° REGPOT-CT2012-316331-POLARIS. Le-Ping Yan  
54  
55 acknowledges the PhD scholarship from FCT (SFRH/BD/64717/2009). The FCT distinction  
56  
57  
58  
59  
60

1  
2  
3 attributed to J.M. Oliveira and A.L. Oliveira under the Investigator FCT program  
4  
5 (IF/00423/2012) and (IF/00411/2013) are also greatly acknowledged.  
6  
7  
8  
9

## 10 **Abbreviations**

11  
12 AAOS: The American Academy of Orthopaedic Surgeons;

13  
14  
15 ACI: Autologous chondrocyte implantation;

16  
17  
18 ACP: Amorphous calcium phosphate;

19  
20  
21 AFSCs: Amniotic fluid-derived stem cells;

22  
23  
24 AOFAS: The American Orthopaedic Foot and Ankle Society;

25  
26  
27 ADSCs: Adipose tissue-derived stem cells;

28  
29  
30 bFGF: Basic fibroblast growth factor;

31  
32  
33  $\beta$ -GP:  $\beta$ -glycerol phosphate;

34  
35  
36 BMP-2: Bone morphogenetic protein-2;

37  
38  
39 BMSCs: Bone marrow-derived stem cells;

40  
41  
42 CAD: Computer-aided design;

43  
44  
45 CAM: Computer-aided manufacture;

46  
47  
48 CaP: Calcium phosphate;

49  
50  
51 Col: Collagen;

52  
53  
54 CPM: Continued positive motion;

55  
56  
57 DMEM: Dulbecco's modified Eagle's medium;

58  
59  
60 ECM: Extracellular matrix;

ESCs: Embryonic stem cells;

FBS: Fetal bovine serum;

1  
2  
3 FDM: Fused deposition modeling;  
4

5  
6 FFI: The Foot Function Index;  
7

8 GAG: Glycosaminoglycan;  
9

10 HA: Hydroxyapatite;  
11

12 hBMSCs: Human BMSCs;  
13

14  
15 IGF-1: Insulin-like growth factor-1;  
16

17 IKDC: International Knee Documentation Committee;  
18

19  
20 IAM: Intermittent active motion;  
21

22 Imm: Immobilization;  
23

24 iPSCs: Induced pluripotent stem cells;  
25

26  
27 KOOS: Knee injury and Osteoarthritis Outcome Score;  
28

29 MACI: Matrix-associated chondrocyte implantation;  
30

31  
32 MASI: Matrix-associated stem cells implantation;  
33

34 Micro-CT: Micro-computed tomography;  
35

36 MMP-13: Matrix metalloproteinase-13;  
37

38  
39 MOCART: Magnetic Resonance Observation of Cartilage Repair Tissue;  
40

41 MRI: Magnetic resonance imaging;  
42

43 MSCs: Mesenchymal stem/stromal cells;  
44

45  
46 OATS: Osteochondral autograft transplantation;  
47

48 OC: Osteochondral;  
49

50  
51 OCD: Osteochondral defects;  
52

53 OLTs: Osteochondral lesion of the talus;  
54

55 OPF: Poly(ethylene glycol) fumarate hydrogels;  
56  
57  
58  
59  
60

1  
2  
3 PBT: Poly(butylene terephthalate);  
4  
5 PCL: Poly( $\epsilon$ -caprolactone);  
6  
7  
8 PDLA: Poly(D-lactic acid);  
9  
10  
11 PLLA: Poly(L-lactic acid);  
12  
13 PEOT: Poly(ethylene oxide terephthalate)  
14  
15 PGA: Poly(glycolic acid);  
16  
17  
18 PLGA: Poly(lactic-co-glycolic acid);  
19  
20 PRP: Platelet-rich plasma;  
21  
22 PTHrP: Parathyroid hormone-related protein;  
23  
24  
25 Ref: Reference;  
26  
27 rhBMP: Recombinant human BMP;  
28  
29 rhIGF: Recombinant human insulin-like growth factor;  
30  
31  
32 SF-36: Patient outcome scores;  
33  
34 TCP: Tricalcium phosphate;  
35  
36 TGF- $\beta$ 1: Transforming growth factor- $\beta$ 1;  
37  
38 TGF- $\beta$ 3: Transforming growth factor- $\beta$ 3;  
39  
40  
41 TRE: Tetracycline-responsible element;  
42  
43  
44 UCMSCs: Umbilical cord mesenchymal stromal cells.  
45  
46  
47

## 48 **References**

49  
50 (1) Moutos, F. T.; Freed, L. E.; Guilak, F. A biomimetic three-dimensional woven composite  
51 scaffold for functional tissue engineering of cartilage. *Nat Mater* **2007**, *6*, 162-167.  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- (2) Mano, J. F.; Reis, R. L. Osteochondral defects: present situation and tissue engineering approaches. *J Tissue Eng Regen Med* **2007**, *1*, 261-273.
  - (3) Gomoll, A. H.; Madry, H.; Knutsen, G.; van Dijk, N.; Seil, R.; Brittberg, M.; Kon, E. The subchondral bone in articular cartilage repair: current problems in the surgical management. *Knee Surg Sports Traumatol Arthrosc* **2010**, *18*, 434-447.
  - (4) Zengerink, M.; Struijs, P. A.; Tol, J. L.; van Dijk, C. N. Treatment of osteochondral lesions of the talus: a systematic review. *Knee Surg Sports Traumatol Arthrosc* **2010**, *18*, 238-246.
  - (5) Weil, L., Jr. Biologics in foot and ankle surgery. *Foot Ankle Spec* **2011**, *4*, 249-252.
  - (6) Lee, B. J.; Christino, M. A.; Daniels, A. H.; Hulstyn, M. J.; Ebersson, C. P. Adolescent patellar osteochondral fracture following patellar dislocation. *Knee Surg Sports Traumatol Arthrosc* **2013**, *21*, 1856-1861.
  - (7) Bitton, R. The economic burden of osteoarthritis. *Am J Manag Care* **2009**, *15*, S230-235.
  - (8) Minas, T.; Gomoll, A. H.; Rosenberger, R.; Royce, R. O.; Bryant, T. Increased failure rate of autologous chondrocyte implantation after previous treatment with marrow stimulation techniques. *Am J Sports Med* **2009**, *37*, 902-908.
  - (9) Kreuz, P. C.; Steinwachs, M. R.; Erggelet, C.; Krause, S. J.; Konrad, G.; Uhl, M.; Sudkamp, N. Results after microfracture of full-thickness chondral defects in different compartments in the knee. *Osteoarthr Cartilage* **2006**, *14*, 1119-1125.
  - (10) Espregueira-Mendes, J.; Pereira, H.; Sevivas, N.; Varanda, P.; da Silva, M. V.; Monteiro, A.; Oliveira, J. M.; Reis, R. L. Osteochondral transplantation using autografts from the upper tibio-fibular joint for the treatment of knee cartilage lesions. *Knee Surg Sports Traumatol Arthrosc* **2012**, *20*, 1136-1142.

- 1  
2  
3 (11) Hangody, L.; Dobos, J.; Balo, E.; Panics, G.; Hangody, L. R.; Berkes, I. Clinical  
4 experiences with autologous osteochondral mosaicplasty in an athletic population: a 17-year  
5 prospective multicenter study. *Am J Sports Med* **2010**, *38*, 1125-1133.  
6  
7  
8  
9  
10 (12) Kon, E.; Verdonk, P.; Condello, V.; Delcogliano, M.; Dhollander, A.; Filardo, G.;  
11 Pignotti, E.; Marcacci, M. Matrix-assisted autologous chondrocyte transplantation for the repair  
12 of cartilage defects of the knee: systematic clinical data review and study quality analysis. *Am J*  
13 *Sports Med* **2009**, *37 Suppl 1*, 156S-166S.  
14  
15  
16  
17  
18 (13) Vasiliadis, H. S.; Wasiak, J. Autologous chondrocyte implantation for full thickness  
19 articular cartilage defects of the knee. *Cochrane Database Syst Rev* **2010**, CD003323.  
20  
21  
22  
23 (14) Sundelacruz, S.; Kaplan, D. L. Stem cell- and scaffold-based tissue engineering  
24 approaches to osteochondral regenerative medicine. *Semin Cell Dev Biol* **2009**, *20*, 646-655.  
25  
26  
27  
28 (15) Langer, R.; Vacanti, J. P. Tissue engineering. *Science* **1993**, *260*, 920-926.  
29  
30  
31 (16) Jacobi, M.; Villa, V.; Magnussen, R. A.; Neyret, P. MACI - a new era? *Sports Med*  
32 *Arthrosc Rehabil Ther Technol* **2011**, *3*, 10.  
33  
34  
35 (17) Grayson, W. L.; Chao, P. H.; Marolt, D.; Kaplan, D. L.; Vunjak-Novakovic, G.  
36 Engineering custom-designed osteochondral tissue grafts. *Trends Biotechnol* **2008**, *26*, 181-189.  
37  
38  
39 (18) Nukavarapu, S. P.; Dorcemus, D. L. Osteochondral tissue engineering: current strategies  
40 and challenges. *Biotechnol Adv* **2013**, *31*, 706-721.  
41  
42  
43  
44 (19) Tampieri, A.; Sprio, S.; Sandri, M.; Valentini, F. Mimicking natural bio-mineralization  
45 processes: a new tool for osteochondral scaffold development. *Trends Biotechnol* **2011**, *29*, 526-  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- (20) Giannini, S.; Buda, R.; Vannini, F.; Di Caprio, F.; Grigolo, B. Arthroscopic autologous chondrocyte implantation in osteochondral lesions of the talus: Surgical technique and results. *Am J Sports Med* **2008**, *36*, 873-880.
- (21) Joshi, N.; Reverte-Vinaixa, M.; Diaz-Ferreiro, E. W.; Dominguez-Oronoz, R. Synthetic resorbable scaffolds for the treatment of isolated patellofemoral cartilage defects in young patients: magnetic resonance imaging and clinical evaluation. *Am J Sports Med* **2012**, *40*, 1289-1295.
- (22) Kon, E.; Delcogliano, M.; Filardo, G.; Pressato, D.; Busacca, M.; Grigolo, B.; Desando, G.; Marcacci, M. A novel nano-composite multi-layered biomaterial for treatment of osteochondral lesions: technique note and an early stability pilot clinical trial. *Injury* **2010**, *41*, 693-701.
- (23) Cheng, H. W.; Luk, K. D.; Cheung, K. M.; Chan, B. P. In vitro generation of an osteochondral interface from mesenchymal stem cell-collagen microspheres. *Biomaterials* **2011**, *32*, 1526-1535.
- (24) Giannini, S.; Buda, R.; Vannini, F.; Cavallo, M.; Grigolo, B. One-step bone marrow-derived cell transplantation in talar osteochondral lesions. *Clin Orthop Relat Res* **2009**, *467*, 3307-3320.
- (25) Jin, C. Z.; Cho, J. H.; Choi, B. H.; Wang, L. M.; Kim, M. S.; Park, S. R.; Yoon, J. H.; Oh, H. J.; Min, B. H. The maturity of tissue-engineered cartilage in vitro affects the reparability for osteochondral defect. *Tissue Eng Part A* **2011**, *17*, 3057-3065.
- (26) Oliveira, J. M.; Rodrigues, M. T.; Silva, S. S.; Malafaya, P. B.; Gomes, M. E.; Viegas, C. A.; Dias, I. R.; Azevedo, J. T.; Mano, J. F.; Reis, R. L. Novel hydroxyapatite/chitosan bilayered

1  
2  
3 scaffold for osteochondral tissue-engineering applications: Scaffold design and its performance  
4 when seeded with goat bone marrow stromal cells. *Biomaterials* **2006**, *27*, 6123-6137.

5  
6  
7  
8 (27) Malafaya, P. B.; Pedro, A. J.; Peterbauer, A.; Gabriel, C.; Redl, H.; Reis, R. L. Chitosan  
9 particles agglomerated scaffolds for cartilage and osteochondral tissue engineering approaches  
10 with adipose tissue derived stem cells. *J Mater Sci: Mater Med* **2005**, *16*, 1077-1085.

11  
12  
13 (28) Guo, X.; Park, H.; Liu, G.; Liu, W.; Cao, Y.; Tabata, Y.; Kasper, F. K.; Mikos, A. G. In  
14 vitro generation of an osteochondral construct using injectable hydrogel composites  
15 encapsulating rabbit marrow mesenchymal stem cells. *Biomaterials* **2009**, *30*, 2741-2752.

16  
17  
18 (29) Augst, A.; Marolt, D.; Freed, L. E.; Vepari, C.; Meinel, L.; Farley, M.; Fajardo, R.; Patel,  
19 N.; Gray, M.; Kaplan, D. L.; Vunjak-Novakovic, G. Effects of chondrogenic and osteogenic  
20 regulatory factors on composite constructs grown using human mesenchymal stem cells, silk  
21 scaffolds and bioreactors. *J R Soc Interface* **2008**, *5*, 929-939.

22  
23  
24 (30) St-Pierre, J. P.; Gan, L.; Wang, J.; Pilliar, R. M.; Gryn timer, M. D.; Kandel, R. A. The  
25 incorporation of a zone of calcified cartilage improves the interfacial shear strength between in  
26 vitro-formed cartilage and the underlying substrate. *Acta Biomater* **2012**, *8*, 1603-1615.

27  
28  
29 (31) Scotti, C.; Wirz, D.; Wolf, F.; Schaefer, D. J.; Burgin, V.; Daniels, A. U.; Valderrabano,  
30 V.; Candrian, C.; Jakob, M.; Martin, I.; Barbero, A. Engineering human cell-based, functionally  
31 integrated osteochondral grafts by biological bonding of engineered cartilage tissues to bony  
32 scaffolds. *Biomaterials* **2010**, *31*, 2252-2259.

33  
34  
35 (32) Grayson, W. L.; Bhumiratana, S.; Grace Chao, P. H.; Hung, C. T.; Vunjak-Novakovic, G.  
36 Spatial regulation of human mesenchymal stem cell differentiation in engineered osteochondral  
37 constructs: effects of pre-differentiation, soluble factors and medium perfusion. *Osteoarthr*  
38 *Cartilage* **2010**, *18*, 714-723.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- (33) Ho, S. T. B.; Cool, S. M.; Hui, J. H.; Hutmacher, D. W. The influence of fibrin based hydrogels on the chondrogenic differentiation of human bone marrow stromal cells. *Biomaterials* **2010**, *31*, 38-47.
- (34) Zhou, J.; Xu, C.; Wu, G.; Cao, X.; Zhang, L.; Zhai, Z.; Zheng, Z.; Chen, X.; Wang, Y. In vitro generation of osteochondral differentiation of human marrow mesenchymal stem cells in novel collagen-hydroxyapatite layered scaffolds. *Acta Biomater* **2011**, *7*, 3999-4006.
- (35) Hung, C. T.; Lima, E. G.; Mauck, R. L.; Takai, E.; LeRoux, M. A.; Lu, H. H.; Stark, R. G.; Guo, X. E.; Ateshian, G. A. Anatomically shaped osteochondral constructs for articular cartilage repair. *J Biomech* **2003**, *36*, 1853-1864.
- (36) Guo, X.; Liao, J.; Park, H.; Saraf, A.; Raphael, R. M.; Tabata, Y.; Kasper, F. K.; Mikos, A. G. Effects of TGF-beta3 and preculture period of osteogenic cells on the chondrogenic differentiation of rabbit marrow mesenchymal stem cells encapsulated in a bilayered hydrogel composite. *Acta Biomater* **2010**, *6*, 2920-2931.
- (37) Dormer, N. H.; Singh, M.; Wang, L.; Berklund, C. J.; Detamore, M. S. Osteochondral interface tissue engineering using macroscopic gradients of bioactive signals. *Ann Biomed Eng* **2010**, *38*, 2167-2182.
- (38) Wang, X.; Wenk, E.; Zhang, X.; Meinel, L.; Vunjak-Novakovic, G.; Kaplan, D. L. Growth factor gradients via microsphere delivery in biopolymer scaffolds for osteochondral tissue engineering. *J Control Release* **2009**, *134*, 81-90.
- (39) McCanless, J. D.; Jennings, L. K.; Cole, J. A.; Bumgardner, J. D.; Haggard, W. O. In vitro differentiation and biocompatibility of mesenchymal stem cells on a novel platelet releasate-containing injectable composite. *J Biomed Mater Res A* **2012**, *100*, 220-229.

- 1  
2  
3  
4 (40) Erisken, C.; Kalyon, D. M.; Wang, H.; Ornek-Ballanco, C.; Xu, J. Osteochondral tissue  
5 formation through adipose-derived stromal cell differentiation on biomimetic polycaprolactone  
6 nanofibrous scaffolds with graded insulin and Beta-glycerophosphate concentrations. *Tissue Eng*  
7  
8 *Pt A* **2011**, *17*, 1239-1252.  
9  
10  
11  
12 (41) Wang, L.; Zhao, L.; Detamore, M. S. Human umbilical cord mesenchymal stromal cells  
13 in a sandwich approach for osteochondral tissue engineering. *J Tissue Eng Regen Med* **2011**, *5*,  
14  
15 712-721.  
16  
17  
18  
19 (42) Rodrigues, M. T.; Lee, S. J.; Gomes, M. E.; Reis, R. L.; Atala, A.; Yoo, J. J. Bilayered  
20 constructs aimed at osteochondral strategies: The influence of medium supplements in the  
21 osteogenic and chondrogenic differentiation of amniotic fluid-derived stem cells. *Acta Biomater*  
22  
23 **2012**, *8*, 2795-2806.  
24  
25  
26  
27 (43) Khanarian, N. T.; Haney, N. M.; Burga, R. A.; Lu, H. H. A functional agarose-  
28 hydroxyapatite scaffold for osteochondral interface regeneration. *Biomaterials* **2012**, *33*, 5247-  
29  
30 5258.  
31  
32  
33  
34 (44) Jiang, J.; Tang, A.; Ateshian, G. A.; Guo, X. E.; Hung, C. T.; Lu, H. H. Bioactive  
35 stratified polymer ceramic-hydrogel scaffold for integrative osteochondral repair. *Ann Biomed*  
36  
37 *Eng* **2010**, *38*, 2183-2196.  
38  
39  
40  
41 (45) Khanarian, N. T.; Jiang, J.; Wan, L. Q.; Mow, V. C.; Lu, H. H. A hydrogel-mineral  
42 composite scaffold for osteochondral interface tissue engineering. *Tissue Eng Pt A* **2012**, *18*,  
43  
44 533-545.  
45  
46  
47  
48 (46) Allan, K. S.; Pilliar, R. M.; Wang, J.; Grynblas, M. D.; Kandel, R. A. Formation of  
49 biphasic constructs containing cartilage with a calcified zone interface. *Tissue Eng* **2007**, *13*,  
50  
51 167-177.  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 (47) Chen, K.; Teh, T. K. H.; Ravi, S.; Toh, S. L.; Goh, J. C. H. Osteochondral interface  
4 generation by rabbit bone marrow stromal cells and osteoblasts coculture. *Tissue Eng Pt A* **2012**,  
5  
6 *18*, 1902-1911.  
7  
8  
9  
10 (48) Chen, K.; Shi, P.; Teh, T. K. H.; Toh, S. L.; Goh, J. C. In vitro generation of a  
11 multilayered osteochondral construct with an osteochondral interface using rabbit bone marrow  
12 stromal cells and a silk peptide-based scaffold. *J Tissue Eng Regen Med* **2013**, in press.  
13  
14  
15 (49) Hui, J. H.; Ren, X.; Afizah, M. H.; Chian, K. S.; Mikos, A. G. Oligo[poly(ethylene  
16 glycol)fumarate] hydrogel enhances osteochondral repair in porcine femoral condyle defects.  
17  
18  
19  
20  
21  
22  
23  
24  
25 (50) Tampieri, A.; Sandri, M.; Landi, E.; Pressato, D.; Francioli, S.; Quarto, R.; Martin, I.  
26 Design of graded biomimetic osteochondral composite scaffolds. *Biomaterials* **2008**, *29*, 3539-  
27 3546.  
28  
29  
30  
31 (51) Igarashi, T.; Iwasaki, N.; Kasahara, Y.; Minami, A. A cellular implantation system using  
32 an injectable ultra-purified alginate gel for repair of osteochondral defects in a rabbit model. *J*  
33  
34  
35  
36  
37  
38  
39 (52) Abarrategi, A.; Lopiz-Morales, Y.; Ramos, V.; Civantos, A.; Lopez-Duran, L.; Marco, F.;  
40 Lopez-Lacomba, J. L. Chitosan scaffolds for osteochondral tissue regeneration. *J Biomed Mater*  
41  
42  
43  
44  
45  
46 (53) Jansen, E. J. P.; Pieper, J.; Gijbels, M. J. J.; Guldemon, N. A.; Riesle, J.; Van Rhijn, L.  
47 W.; Bulstra, S. K.; Kuijjer, R. PEOT/PBT based scaffolds with low mechanical properties  
48 improve cartilage repair tissue formation in osteochondral defects. *J Biomed Mater Res A* **2009**,  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 (54) Ikeda, R.; Fujioka, H.; Nagura, I.; Kokubu, T.; Toyokawa, N.; Inui, A.; Makino, T.;  
4  
5 Kaneko, H.; Doita, M.; Kurosaka, M. The effect of porosity and mechanical property of a  
6  
7 synthetic polymer scaffold on repair of osteochondral defects. *Int Orthop* **2009**, *33*, 821-828.  
8  
9  
10 (55) Duan, P.; Pan, Z.; Cao, L.; He, Y.; Wang, H.; Qu, Z.; Dong, J.; Ding, J. The effects of  
11  
12 pore size in bilayered poly(lactide-co-glycolide) scaffolds on restoring osteochondral defects in  
13  
14 rabbits. *J Biomed Mater Res A* **2013**, *102*, 180-192.  
15  
16  
17 (56) D'Onofrio, A.; Cresce, G. D.; Bolgan, I.; Magagna, P.; Piccin, C.; Auriemma, S.; Fabbri,  
18  
19 A. Clinical and hemodynamic outcomes after aortic valve replacement with stented and stentless  
20  
21 pericardial xenografts: a propensity-matched analysis. *J Heart Valve Dis* **2011**, *20*, 319-325.  
22  
23  
24 (57) Ricchetti, E. T.; Aurora, A.; Iannotti, J. P.; Derwin, K. A. Scaffold devices for rotator  
25  
26 cuff repair. *J Shoulder Elbow Surg* **2012**, *21*, 251-265.  
27  
28  
29 (58) Emans, P. J.; Hulsbosch, M.; Wetzels, G. M.; Bulstra, S. K.; Kuijjer, R. Repair of  
30  
31 osteochondral defects in rabbits with ectopically produced cartilage. *Tissue Eng* **2005**, *11*, 1789-  
32  
33 1796.  
34  
35  
36 (59) Yagihashi, K.; Miyazawa, K.; Togari, K.; Goto, S. Demineralized dentin matrix acts as a  
37  
38 scaffold for repair of articular cartilage defects. *Calcif Tissue Int* **2009**, *84*, 210-220.  
39  
40  
41 (60) Yang, Q.; Peng, J.; Lu, S. B.; Guo, Q. Y.; Zhao, B.; Zhang, L.; Wang, A. Y.; Xu, W. J.;  
42  
43 Xia, Q.; Ma, X. L.; Hu, Y. C.; Xu, B. S. Evaluation of an extracellular matrix-derived acellular  
44  
45 biphasic scaffold/cell construct in the repair of a large articular high-load-bearing osteochondral  
46  
47 defect in a canine model. *Chin Med J (Engl)* **2011**, *124*, 3930-3938.  
48  
49  
50 (61) Yan, L-P.; Silva-Correia J.; Oliveira, M. B.; Vilela, C.; Pereira, H.; Sousa, R. A.; Mano,  
51  
52 J. F.; Oliveira, A. L.; Oliveira, J. M.; Reis, R. L. Bilayered silk/silk-NanoCaP scaffolds for  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 osteochondral tissue engineering: In vitro and in vivo assessment of biological performance.

4  
5  
6 *Acta Biomater* **2015**, *12*, 227-241.

7  
8 (62) Jiang, C. C.; Chiang, H.; Liao, C. J.; Lin, Y. J.; Kuo, T. F.; Shieh, C. S.; Huang, Y. Y.;  
9  
10 Tuan, R. S. Repair of porcine articular cartilage defect with a biphasic osteochondral composite.  
11  
12 *J Orthop Res* **2007**, *25*, 1277-1290.

13  
14  
15 (63) Shao, X.; Goh, J. C.; Hutmacher, D. W.; Lee, E. H.; Zigang, G. Repair of large articular  
16  
17 osteochondral defects using hybrid scaffolds and bone marrow-derived mesenchymal stem cells  
18  
19 in a rabbit model. *Tissue Eng* **2006**, *12*, 1539-1551.

20  
21  
22 (64) Da, H.; Jia, S. J.; Meng, G. L.; Cheng, J. H.; Zhou, W.; Xiong, Z.; Mu, Y. J.; Liu, J. The  
23  
24 Impact of Compact Layer in Biphasic Scaffold on Osteochondral Tissue Engineering. *PLoS ONE*  
25  
26 **2013**, *8*, e54838.

27  
28  
29 (65) Liu, L.; Xiong, Z.; Zhang, R.; Jin, L.; Yan, Y. A novel osteochondral scaffold fabricated  
30  
31 via multi-nozzle low-temperature deposition manufacturing. *J Bioact Compat Pol* **2009**, *24*, 18-  
32  
33 30.

34  
35  
36 (66) Huang, X.; Yang, D.; Yan, W.; Shi, Z.; Feng, J.; Gao, Y.; Weng, W.; Yan, S.  
37  
38 Osteochondral repair using the combination of fibroblast growth factor and amorphous calcium  
39  
40 phosphate/poly(L-lactic acid) hybrid materials. *Biomaterials* **2007**, *28*, 3091-3100.

41  
42  
43 (67) Reyes, R.; Delgado, A.; Sanchez, E.; Fernandez, A.; Hernandez, A.; Evora, C. Repair of  
44  
45 an osteochondral defect by sustained delivery of BMP-2 or TGFbeta1 from a bilayered alginate-  
46  
47 PLGA scaffold. *J Tissue Eng Regen Med* **2014**, *8*, 521-533.

48  
49  
50 (68) Reyes, R.; Delgado, A.; Solis, R.; Sanchez, E.; Hernandez, A.; San Roman, J.; Evora, C.  
51  
52 Cartilage repair by local delivery of TGF-beta1 or BMP-2 from a novel, segmented  
53  
54

1  
2  
3 polyurethane/poly(lactic-co-glycolic) bilayered scaffold. *J Biomed Mater Res A* **2014**, *102*, 1110-  
4  
5  
6 1120.

7  
8 (69) Kim, K.; Lam, J.; Lu, S.; Spicer, P. P.; Lueckgen, A.; Tabata, Y.; Wong, M. E.; Jansen, J.  
9  
10 A.; Mikos, A. G.; Kasper, F. K. Osteochondral tissue regeneration using a bilayered composite  
11  
12 hydrogel with modulating dual growth factor release kinetics in a rabbit model. *J Control*  
13  
14 *Release* **2013**, *168*, 166-178.

15  
16  
17 (70) Dormer, N. H.; Singh, M.; Zhao, L.; Mohan, N.; Berkland, C. J.; Detamore, M. S.  
18  
19 Osteochondral interface regeneration of the rabbit knee with macroscopic gradients of bioactive  
20  
21 signals. *J Biomed Mater Res A* **2012**, *100*, 162-170.

22  
23  
24 (71) Mohan, N.; Dormer, N. H.; Caldwell, K. L.; Key, V. H.; Berkland, C. J.; Detamore, M. S.  
25  
26 Continuous gradients of material composition and growth factors for effective regeneration of  
27  
28 the osteochondral interface. *Tissue Eng Part A* **2011**, *17*, 2845-2855.

29  
30  
31 (72) Marmotti, A.; Bruzzone, M.; Bonasia, D. E.; Castoldi, F.; Rossi, R.; Piras, L.; Maiello,  
32  
33 A.; Realmuto, C.; Peretti, G. M. One-step osteochondral repair with cartilage fragments in a  
34  
35 composite scaffold. *Knee Surg Sports Traumatol Arthrosc* **2012**, *20*, 2590-2601.

36  
37  
38 (73) Xie, X.; Wang, Y.; Zhao, C.; Guo, S.; Liu, S.; Jia, W.; Tuan, R. S.; Zhang, C.  
39  
40 Comparative evaluation of MSCs from bone marrow and adipose tissue seeded in PRP-derived  
41  
42 scaffold for cartilage regeneration. *Biomaterials* **2012**, *33*, 7008-7018.

43  
44  
45 (74) Sun, Y.; Feng, Y.; Zhang, C. Q.; Chen, S. B.; Cheng, X. G. The regenerative effect of  
46  
47 platelet-rich plasma on healing in large osteochondral defects. *Int Orthop* **2010**, *34*, 589-597.

48  
49  
50 (75) Chen, J.; Chen, H.; Li, P.; Diao, H.; Zhu, S.; Dong, L.; Wang, R.; Guo, T.; Zhao, J.;  
51  
52 Zhang, J. Simultaneous regeneration of articular cartilage and subchondral bone in vivo using  
53  
54



1  
2  
3 MSCs induced by a spatially controlled gene delivery system in bilayered integrated scaffolds.

4  
5  
6 *Biomaterials* **2011**, *32*, 4793-4805.

7  
8 (76) Zhang, W.; Chen, J.; Tao, J.; Hu, C.; Chen, L.; Zhao, H.; Xu, G.; Heng, B. C.; Ouyang,  
9  
10 H. W. The promotion of osteochondral repair by combined intra-articular injection of  
11  
12 parathyroid hormone-related protein and implantation of a bi-layer collagen-silk scaffold.

13  
14  
15 *Biomaterials* **2013**, *34*, 6046-6057.

16  
17 (77) Chen, H. C.; Chang, Y. H.; Chuang, C. K.; Lin, C. Y.; Sung, L. Y.; Wang, Y. H.; Hu, Y.  
18  
19 C. The repair of osteochondral defects using baculovirus-mediated gene transfer with de-  
20  
21 differentiated chondrocytes in bioreactor culture. *Biomaterials* **2009**, *30*, 674-681.

22  
23 (78) Leng, P.; Ding, C. R.; Zhang, H. N.; Wang, Y. Z. Reconstruct large osteochondral defects  
24  
25 of the knee with hIGF-1 gene enhanced Mosaicplasty. *Knee* **2012**, *19*, 804-811.

26  
27 (79) Sato, M.; Shin-ya, K.; Lee, J. I.; Ishihara, M.; Nagai, T.; Kaneshiro, N.; Mitani, G.;  
28  
29 Tahara, H.; Mochida, J. Human telomerase reverse transcriptase and glucose-regulated protein  
30  
31 78 increase the life span of articular chondrocytes and their repair potential. *BMC Musculoskelet*  
32  
33 *Dis* **2012**, *13*, 51.

34  
35 (80) Sun, J.; Hou, X. K.; Li, X.; Tang, T. T.; Zhang, R. M.; Kuang, Y.; Shi, M. Mosaicplasty  
36  
37 associated with gene enhanced tissue engineering for the treatment of acute osteochondral  
38  
39 defects in a goat model. *Arch Orthop Trauma Surg* **2009**, *129*, 757-771.

40  
41 (81) Zheng, Y. H.; Su, K.; Jian, Y. T.; Kuang, S. J.; Zhang, Z. G. Basic fibroblast growth  
42  
43 factor enhances osteogenic and chondrogenic differentiation of human bone marrow  
44  
45 mesenchymal stem cells in coral scaffold constructs. *J Tissue Eng Regen Med* **2011**, *5*, 540-550.

46  
47 (82) Li, B.; Yang, J.; Ma, L.; Li, F.; Tu, Z.; Gao, C. Fabrication of poly(lactide-co-glycolide)  
48  
49 scaffold filled with fibrin gel, mesenchymal stem cells, and poly(ethylene oxide)-b-poly(L-  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 lysine)/TGF-beta1 plasmid DNA complexes for cartilage restoration in vivo. *J Biomed Mater*  
4  
5  
6 *Res A* **2013**, *101*, 3097-3108.

7  
8 (83) Madry, H.; Kaul, G.; Zurakowski, D.; Vunjak-Novakovic, G.; Cucchiarini, M. Cartilage  
9  
10 constructs engineered from chondrocytes overexpressing IGF-I improve the repair of  
11  
12 osteochondral defects in a rabbit model. *Eur Cells Mater* **2012**, *25*, 229-247.

13  
14 (84) Ueblacker, P.; Wagner, B.; Vogt, S.; Salzman, G.; Wexel, G.; Kruger, A.; Plank, C.;  
15  
16 Brill, T.; Specht, K.; Hennig, T.; Schillinger, U.; Imhoff, A. B.; Martinek, V.; Gansbacher, B. In  
17  
18 vivo analysis of retroviral gene transfer to chondrocytes within collagen scaffolds for the  
19  
20 treatment of osteochondral defects. *Biomaterials* **2007**, *28*, 4480-4487.

21  
22 (85) Chang, N. J.; Lin, C. C.; Li, C. F.; Wang, D. A.; Issariyaku, N.; Yeh, M. L. The  
23  
24 combined effects of continuous passive motion treatment and acellular PLGA implants on  
25  
26 osteochondral regeneration in the rabbit. *Biomaterials* **2012**, *33*, 3153-3163.

27  
28 (86) Chang, N. J.; Lin, C. C.; Li, C. F.; Su, K.; Yeh, M. L. The effect of osteochondral  
29  
30 regeneration using polymer constructs and continuous passive motion therapy in the lower  
31  
32 weight-bearing zone of femoral trocheal groove in rabbits. *Ann Biomed Eng* **2013**, *41*, 385-397.

33  
34 (87) Pietschmann, M. F.; Horng, A.; Niethammer, T.; Pagenstert, I.; Sievers, B.; Jansson, V.;  
35  
36 Glaser, C.; Müller, P. E. Cell quality affects clinical outcome after MACI procedure for cartilage  
37  
38 injury of the knee. *Knee Surg Sports Traumatol Arthrosc* **2009**, *17*, 1305-1311.

39  
40 (88) Bedi, A.; Foo, L. F.; Williams Iii, R. J.; Potter, H. G. The maturation of synthetic  
41  
42 scaffolds for osteochondral donor sites of the knee: An MRI and T2-mapping analysis. *Cartilage*  
43  
44  
45  
46  
47  
48  
49  
50  
51 **2010**, *1*, 20-28.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- (89) Giza, E.; Sullivan, M.; Ocel, D.; Lundeen, G.; Mitchell, M. E.; Veris, L.; Walton, J. Matrix-induced autologous chondrocyte implantation of talus articular defects. *Foot Ankle Int* **2010**, *31*, 747-753.
- (90) Aurich, M.; Bedi, H. S.; Smith, P. J.; Rolauffs, B.; Mückley, T.; Clayton, J.; Blackney, M. Arthroscopic treatment of osteochondral lesions of the ankle with matrix-associated chondrocyte implantation: Early clinical and magnetic resonance imaging results. *Am J Sports Med* **2011**, *39*, 311-319.
- (91) Barber, F. A.; Dockery, W. D. A computed tomography scan assessment of synthetic multiphase polymer scaffolds used for osteochondral defect repair. *Arthroscopy* **2011**, *27*, 60-64.
- (92) Kon, E.; Delcogliano, M.; Filardo, G.; Busacca, M.; Di Martino, A.; Marcacci, M. Novel nano-composite multilayered biomaterial for osteochondral regeneration: a pilot clinical trial. *Am J Sports Med* **2011**, *39*, 1180-1190.
- (93) Macmull, S.; Parratt, M. T.; Bentley, G.; Skinner, J. A.; Carrington, R. W.; Morris, T.; Briggs, T. W. Autologous chondrocyte implantation in the adolescent knee. *Am J Sports Med* **2011**, *39*, 1723-1730.
- (94) Dhollander, A. A. M.; Liekens, K.; Almqvist, K. F.; Verdonk, R.; Lambrecht, S.; Elewaut, D.; Verbruggen, G.; Verdonk, P. C. M. A pilot study of the use of an osteochondral scaffold plug for cartilage repair in the knee and how to deal with early clinical failures. *Arthroscopy* **2012**, *28*, 225-233.
- (95) Kon, E.; Vannini, F.; Buda, R.; Filardo, G.; Cavallo, M.; Ruffilli, A.; Nanni, M.; Di Martino, A.; Marcacci, M.; Giannini, S. How to treat osteochondritis dissecans of the knee: Surgical techniques and new trends AAOS exhibit selection. *J Bone Joint Surg Am* **2012**, *94*, e1.(1-8).

- 1  
2  
3 (96) Chiang, H.; Liao, C. J.; Hsieh, C. H.; Shen, C. Y.; Huang, Y. Y.; Jiang, C. C. Clinical  
4 feasibility of a novel biphasic osteochondral composite for matrix-associated autologous  
5 chondrocyte implantation. *Osteoarthr Cartilage* **2013**, *21*, 589-598.  
6  
7  
8  
9  
10 (97) Panseri, S.; Russo, A.; Cunha, C.; Bondi, A.; Di Martino, A.; Patella, S.; Kon, E.  
11 Osteochondral tissue engineering approaches for articular cartilage and subchondral bone  
12 regeneration. *Knee Surg Sports Traumatol Arthrosc* **2012**, *20*, 1182-1191.  
13  
14  
15  
16  
17 (98) Nejadnik, H.; Daldrup-Link, H. E. Engineering stem cells for treatment of osteochondral  
18 defects. *Skeletal Radiol* **2012**, *41*, 1-4.  
19  
20  
21  
22 (99) Nejadnik, H.; Hui, J. H.; Feng Choong, E. P.; Tai, B. C.; Lee, E. H. Autologous bone  
23 marrow-derived mesenchymal stem cells versus autologous chondrocyte implantation: an  
24 observational cohort study. *Am J Sports Med* **2010**, *38*, 1110-1116.  
25  
26  
27  
28  
29 (100) Getgood, A. M.; Kew, S. J.; Brooks, R.; Aberman, H.; Simon, T.; Lynn, A. K.; Rushton,  
30 N. Evaluation of early-stage osteochondral defect repair using a biphasic scaffold based on a  
31 collagen-glycosaminoglycan biopolymer in a caprine model. *Knee* **2012**, *19*, 422-430.  
32  
33  
34  
35  
36 (101) Ding, C.; Qiao, Z.; Jiang, W.; Li, H.; Wei, J.; Zhou, G.; Dai, K. Regeneration of a goat  
37 femoral head using a tissue-specific, biphasic scaffold fabricated with CAD/CAM technology.  
38  
39  
40  
41 *Biomaterials* **2013**, *34*, 6706-6716.  
42  
43  
44 (102) Fedorovich, N. E.; Schuurman, W.; Wijnberg, H. M.; Prins, H. J.; Van Weeren, P. R.;  
45 Malda, J.; Alblas, J.; Dhert, W. J. A. Biofabrication of osteochondral tissue equivalents by  
46 printing topologically defined, cell-laden hydrogel scaffolds. *Tissue Eng Pt C-Meth* **2012**, *18*, 33-  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60 44.

1  
2  
3 (103) Hwang, N. S.; Varghese, S.; Lee, H. J.; Zhang, Z.; Ye, Z.; Bae, J.; Cheng, L.; Elisseeff, J.  
4  
5 In vivo commitment and functional tissue regeneration using human embryonic stem cell-  
6  
7 derived mesenchymal cells. *Proc Natl Acad Sci U S A* **2008**, *105*, 20641-20646.  
8  
9


10 (104) Yamanaka, S. Induced pluripotent stem cells: past, present, and future. *Cell Stem Cell*  
11  
12 **2012**, *10*, 678-684.  
13  
14

15 (105) Ko, J. Y.; Kim, K. I.; Park, S.; Im, G. I. In vitro chondrogenesis and in vivo repair of  
16  
17 osteochondral defect with human induced pluripotent stem cells. *Biomaterials* **2014**, *35*, 3571-  
18  
19 3581.  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## For Table of Contents Use Only

# Current Concepts and Challenges in Osteochondral Tissue Engineering and Regenerative Medicine

*Le-Ping Yan,<sup>†‡</sup> Joaquim M. Oliveira,<sup>\*†‡</sup> Ana L. Oliveira,<sup>†‡§</sup> Rui L. Reis<sup>†‡</sup>*



The left is the micro-CT image of bilayered silk/silk-nanoCaP scaffolds recently developed by our group. This image clearly showed the silk matrix (brown) and the CaP phase (blue) distribution in the biphasic and well integrated scaffold. The right is the Masson's trichrome staining image of the osteochondral explant after implantation of the left bilayered scaffold in rabbit OCD for 4 weeks. Black and white arrows indicate neocartilage tissue formed in the top silk layer and subchondral bone grew into the bottom silk-nanoCaP layer. These silk based bilayered scaffolds could be promising candidate for OC regeneration.